Hassan_et_al-Advanced_Materials.sup-1

合集下载

Endress+Hauser Cerabar S Deltabar S Evolution软件更

Endress+Hauser Cerabar S   Deltabar S Evolution软件更

Manufacturer Informationfor users regarding software updates(following the NAMUR recommendation 53)1Type of deviceField device / signal processing deviceMonitoring- / operation system / hand held terminal etc.Modem / interfaceManufacturer :Endress+Hauser GmbH+Co. KG, 79689 MaulburgDevice :Cerabar S / Deltabar S EvolutionType :PMC71, PMP71/75, PMD70/75, FMD76/77/78Previous software version :02.01.03How can the previous software version number be identified:via HART command #0 / via ToF-Tool or on-site: Group Selection ->Operating Menu --> Transmitter Info --> Transmitter Data -->Software Version2Firmware/SoftwareNew firm-/software version :02.10.40Description of the modification in comparison with the predecessor version:New Level Mode "Easy"Enhanced Safety of Parametrization for Level EasySIL Mode for Level EasyEnhanced Possibilities of LinearizationHART Burst ModeEnhanced possibilities for the use of HistoROMCorrections in:-Low Flow Cut Off for Flow Measurement-Copying Data from HistoROM into transmitter3CompatibilityIs the newly installed firmware/software compatible with the operating tools?YesNo, description:New DD for ToF-Tool needed (available with ToF-Tool V4.00 from week 26/2006)New DD for DXR375 needed (available with DevRev21 from week 26/2006)New DTM for Fieldcare needed (available with FieldCare V02.02.00 from week 27/2006)Manufacturer Informationfor users regarding software updates(following the NAMUR recommendation 53)Is a firm/software update generally recommended?Yes, reasons:The firm-/software update can be performed by means of …No, reasons:The new software enhances the transmitter behaviour in certain applications and use cases, e.g. in easier parametrization in level applications.4Instruction manualIs a new instruction manual necessary due to the modification of the firm-/software? YesNoWhich manual corresponds to the new firm-/software:Device Communication options Manual Marking Cerabar SPMC71,PMP71/75Deltabar SPMD70/75,FMD76/77/78HART HART Cerabar S PMC71, PMP71/75 Pressure Transmitter Deltabar S PMD70/75, FMD76/77/78 Differential Pressure Transmitter BA 271P/00/en/08.06 71027246 Software version 2.10 BA270P/00/en/08.06 71027244 Software version 2.10The new instruction manuals can be referred in Internet: -area …DOWNLOAD“-declaration of the device and kind of manual5PriceChange in price of device in comparison with the predecessor version?Yes, new list price and update costs (without installation) are enclosuredNo。

阿托伐他汀钙治疗急性脑梗死的有效剂量、最适剂量及安全性研究

阿托伐他汀钙治疗急性脑梗死的有效剂量、最适剂量及安全性研究

阿托伐他汀钙治疗急性脑梗死的有效剂量、最适剂量及安全性研究苏丹丹;肖波;毕方方【摘要】目的:探究阿托伐他汀钙对急性脑梗死治疗的有效剂量、最适剂量及安全性。

方法选取治疗的急性脑梗死患者180例作为该研究的对象,对所有的患者按照给药计量的不同分为10 mg组、20 mg组、40 mg组,3组的用药时间均为90 d,对3组用药前、30 d以及90 d的低密度脂蛋白胆固醇( LDL)、总胆固醇( TC)、三酰甘油( TG)、高敏C-反应蛋白(hs-CRP)、内中膜厚度(IMT)、高密度脂蛋白胆固醇(HDL)、卒中量表(NIHSS)、肌酐(Cr)、尿酸(UA)、尿素氮( BUN)、白细胞( WBC)进行观察。

结果3组LDL、TC、TG、HDL水平以及NIHSS的评分在治疗后的30、90 d,均有显著变化,与用药前比较差异有统计学意义( P <0.05);治疗90 d后20 mg组和40 mg组的NIHSS的评分及LDL、TC水平和10 mg组比较差异有统计学意义( P <0.05),治疗90 d后20 mg组和40 mg组之间的LDL、TC水平以及NIHSS 比较差异无统计学意义( P >0.05),治疗90 d后3组组间的TG水平比较差异无统计学意义(P>0.05),治疗90 d 3组间HDL水平比较差异有统计学意义( P <0.05);3组治疗前后IMT均有变化,但差异无统计学意义( P >0.05);治疗后30 d 20 mg组和40 mg组的hs-CRP水平与10 mg组比较差异有统计学意义( P <0.05),20 mg组和40 mg 组NIHSS评分比较差异无统计学意义( P >0.05);90 d时组间的比较差异无统计学意义( P >0.05);CK(肌酸激酶)在90 d时10 mg组和20 mg组的组内比较具有显著的下降( P <0.05),40 mg组的CK在90 d时有升高,但差异无统计学意义( P >0.05);3组的葡萄糖在90 d时均有显著的降低,组内差异有统计学意义( P <0.05),组间的比较差异无统计学意义( P >0.05),没有患者出现新发糖尿病;90 d时各组患者均没有肝酶升高超过正常3倍的;3组用药前后的Cr、UA、BUN、WBC等指标没有显著的变化。

宫颈癌后装腔内照射施源器放置技术与剂量分布对疗效及不良反应的影响

宫颈癌后装腔内照射施源器放置技术与剂量分布对疗效及不良反应的影响

宫颈癌后装腔内照射施源器放置技术与剂量分布对疗效及不良反应的影响白冬梅;赵红;杨卫卫;白胜江;曹彩萍【摘要】目的探讨宫颈癌后装腔内照射施源器放置技术与剂量分布对其疗效的影响.方法选择Ⅱb期后的宫颈鳞癌患者80例作为研究对象,根据放疗方法的不同分为观察组与对照组,各40例,两组放疗都采用6mV X线行四野盒式照射,在腔内后装施源器中,观察组采用扁平固定三管施源器,对照组采用单管施源器,两组都放疗观察8周.结果治疗后观察组与对照组有效率分别为77.5%和70.0%,两组有效率相比无显著性差异(P>0.05).观察组治疗期间膀胱、肠道反应发生率分别为5.0%和7.5%,对照组为22.5%和27.5%,观察组明显低于对照组(P<0.05).随访至今,观察组的总生存时间与无瘤生存时间为(34.23±4.11)个月与(23.14±3.78)个月,对照组分别为(29.12±4.09)个月与(19.10±4.13)个月,观察组均优于对照组(P<0.05).结论单管施源器和三管施源器放射治疗宫颈癌的疗效相当,但是放置技术与剂量分布合理的三管施源器可以减少膀胱、肠道反应发生率,延长患者的生存时间,有很好的应用效果.【期刊名称】《实用癌症杂志》【年(卷),期】2018(033)006【总页数】4页(P1024-1027)【关键词】宫颈癌;施源器;腔内照射;剂量;疗效【作者】白冬梅;赵红;杨卫卫;白胜江;曹彩萍【作者单位】716000 延安大学附属医院;716000 延安大学附属医院;716000 延安大学附属医院;716000 延安大学附属医院;716000 延安大学附属医院【正文语种】中文【中图分类】R737.33宫颈癌是是世界范围内继乳腺癌之后的第二大女性恶性肿瘤,目前国内发病率约10/10万,死亡率约3.3/10万,且年轻患者发病率呈上升趋势[1-2]。

宫颈癌的治疗方法包括手术、放疗、化疗、免疫治疗、生物治疗等,但是很多患者在入院时已为晚期,已经失去了手术治疗的指征[3-4]。

Schneider Electric 产品数据手册 - LUCB05BL高级控制单元说明书

Schneider Electric 产品数据手册 - LUCB05BL高级控制单元说明书

T h e i n f o r m a t i o n p r o v i d e d i n t h i s d o c u m e n t a t i o n c o n t a i n s g e n e r a l d e s c r i p t i o n s a n d /o r t e c h n i c a l c h a r a c t e r i s t i c s o f t h e p e r f o r m a n c e o f t h e p r o d u c t s c o n t a i n e d h e r e i n .T h i s d o c u m e n t a t i o n i s n o t i n t e n d e d a s a s u b s t i t u t e f o r a n d i s n o t t o b e u s e d f o r d e t e r m i n i n g s u i t a b i l i t y o r r e l i a b i l i t y o f t h e s e p r o d u c t s f o r s p e c i f i c u s e r a p p l i c a t i o n s .I t i s t h e d u t y o f a n y s u c h u s e r o r i n t e g r a t o r t o p e r f o r m t h e a p p r o p r i a t e a n d c o m p l e t e r i s k a n a l y s i s , e v a l u a t i o n a n d t e s t i n g o f t h e p r o d u c t s w i t h r e s p e c t t o t h e r e l e v a n t s p e c i f i c a p p l i c a t i o n o r u s e t h e r e o f .N e i t h e r S c h n e i d e r E l e c t r i c I n d u s t r i e s S A S n o r a n y o f i t s a f f i l i a t e s o r s u b s i d i a r i e s s h a l l b e r e s p o n s i b l e o r l i a b l e f o r m i s u s e o f t h e i n f o r m a t i o n c o n t a i n e d h e r e i n .Product data sheetCharacteristicsLUCB05BLadvanced control unit LUCB - class 10 -1.25...5 A - 24 V DCProduct availability: Stock - Normally stocked in distribution facilityMainRange TeSys Product name TeSys U Device short name LUCBProduct or component typeAdvanced control unitProduct specific applica-tionBasic protection and advanced functions, communi-cation Product compatibilityLUFDA10LULC15LULC09LULC033LUFC00LULC07ASILUFC51LULC08LUFW10LUFV2LUFN..LUFDA01LULC031LUFDH11ASILUFC5Utilisation categoryAC-44AC-41AC-43Motor power kW3 KW 690 V AC 50/60 Hz1.5 KW 400...440 V AC 50/60 Hz2.2 kW 500 V AC 50/60 Hz Thermal protection ad-justment range 1.25…5 A [Uc] control circuit volt-age24 V DCThermal overload classClass 10 40…60 Hz -13…158 °F (-25…70 °C) IEC 60947-6-2Class 10 40…60 Hz -13…158 °F (-25…70 °C) UL 508ComplementaryMain function availableProtection against overload and short-circuit Manual resetEarth fault protectionProtection against phase failure and phase imbalance Mounting mode Plug-in Mounting locationFront sideControl circuit voltage limits 20...27 V DC 24 V in operationTypical current consumption130 MA 24 V DC I maximum while closing with LUB12220 MA 24 V DC I maximum while closing with LUB3260 MA 24 V DC I rms sealed with LUB1280 mA 24 V DC I rms sealed with LUB32Operating time35 ms opening with LUB12 control circuit 35 ms opening with LUB32 control circuit 70 ms closing with LUB12 control circuit 70 ms closing with LUB32 control circuit Load type 3-phase motor self-cooled Tripping threshold14.2 x Ir +/- 20 %[Ui] rated insulation voltage600 V UL 508690 V IEC 60947-1600 V CSA C22.2 No 14[Uimp] rated impulse withstand voltage6 kV IEC 60947-6-2Safe separation of circuit400 V SELV between the control and auxiliary circuits IEC 60947-1400 V SELV between the control or auxiliary circuit and the main circuit IEC60947-1EnvironmentHeat dissipation2 W control circuit with LUB123 W control circuit with LUB32Immunity to microbreaks3 msImmunity to voltage dips70 % / 500 ms IEC 61000-4-11Standards UL 508 type E, with phase barrierEN 60947-6-2IEC 60947-6-2CSA C22.2 No 14 type EProduct certifications DNVLROS (Lloyds register of shipping)GOSTATEXABSBVASEFACSACCCGLULIP degree of protection IP20 front panel and wired terminals IEC 60947-1IP20 other faces IEC 60947-1IP40 front panel outside connection zone IEC 60947-1Protective treatment TH IEC 60068Ambient air temperature for operation-13…158 °F (-25…70 °C)Ambient air temperature for storage-40…185 °F (-40…85 °C)Operating altitude6561.68 ft (2000 m)Fire resistance1760 °F (960 °C) parts supporting live components IEC 60695-2-121202 °F (650 °C) IEC 60695-2-12Shock resistance10 gn power poles open IEC 60068-2-2715 gn power poles closed IEC 60068-2-27Vibration resistance 2 gn 5…300 Hz power poles open IEC 60068-2-64 gn 5…300 Hz power poles closed IEC 60068-2-6Resistance to electrostatic discharge8 KV 3 in open air IEC 61000-4-28 kV 4 on contact IEC 61000-4-2Resistance to radiated fields9.14 V/m (10 V/m) 3 IEC 61000-4-3Resistance to fast transients2 KV 3 serial link IEC 61000-4-44 kV 4 all circuits except for serial link IEC 61000-4-4Immunity to radioelectric fields10 V IEC 61000-4-6Ordering and shipping detailsCategory22397 - TESYS U - CNTRL MOD(LUCA,LUCD)Discount Schedule I11GTIN00785901222064Package weight(Lbs)0.13 kg (0.28 lb(US))Returnability YesCountry of origin FROffer SustainabilitySustainable offer status Green Premium productREACh Regulation REACh DeclarationEU RoHS Directive Compliant EU RoHS DeclarationMercury free YesRoHS exemption information YesChina RoHS Regulation China RoHS DeclarationEnvironmental Disclosure Product Environmental ProfileCircularity Profile End Of Life InformationWEEE The product must be disposed on European Union markets following specificwaste collection and never end up in rubbish bins.Contractual warrantyWarranty18 months。

TOTAL CONTENTS

TOTAL CONTENTS

IWater Science and EngineeringISSN 1674-2370, CN 32-1785/TVVol. 13, Nos.1-4 2020TOTAL CONTENTSNo. 1Aggregated morphodynamic modelling of tidal inlets and estuaries.....……………………………………………………………………. Zheng Bing Wang, Ian Townend, Marcel Stive (1) Predicting pollutant removal in constructed wetlands using artificial neural networks (ANNs)..................................................Christopher Kiiza, Shun-qi Pan, Bettina Bockelmann-Evans, Akintunde Babatunde (14) Emergency control of Spartina alterniflora re-invasion with a chemical method in Chongming Dongtan, China .....................................................Zhi-yuan Zhao, Yuan Xu, Lin Yuan, Wei Li, Xiao-jing Zhu, Li-quan Zhang (24) Spatial dynamic patterns of saltmarsh vegetation in southern Hangzhou Bay: Exotic and native species ..............................................................................................................................Si-long Huang, Yi-ning Chen, Yan Li (34) Control of wind-wave power on morphological shape of salt marsh margins...Alvise Finotello, Marco Marani, Luca Carniello, Mattia Pivato, Marcella Roner, Laura Tommasini, Andrea D’alpaos (45) Ecological impact of land reclamation on Jiangsu coast (China): A novel ecotope assessment for Tongzhou Bay ........................................................................... Jos R. M. Muller, Yong-ping Chen, Stefan G. J. Aarninkhof, Ying-Chi Chan, Theunis Piersma, Dirk S. van Maren, Jian-feng Tao, Zheng Bing Wang, Zheng Gong (57) Removal of hexavalent chromium in aquatic solutions by pomelo peel..........................................................................Qiong Wang, Cong Zhou, Yin-jie Kuang, Zhao-hui Jiang, Min Yang (65) Numerical analysis of seabed dynamic response in vicinity of mono-pile under wave-current loading ........................................................................................Jie Lin, Ji-sheng Zhang, Ke Sun, Xing-lin Wei, Ya-kun Guo (74) Thank you to our academic editors and peer reviewers (I)Guide for Authors (II)No. 2Hydrological response to climate change and human activities: A case study of Taihu Basin, China ........................................................................................Juan Wu, Zhi-yong Wu, He-juan Lin, Hai-ping Ji, Min Liu (83) Possibilities of urban flood reduction through distributed-scale rainwater harvesting....................................................................................................Aysha Akter, Ahad Hasan Tanim, Md. Kamrul Islam (95) Toxic response of aquatic organisms to guide application of artemisinin sustained-release granule algaecide ........................................Li-xiao Ni, Na Wang, Xuan-yu Liu, Fei-fei Yue, Yi-fei Wang, Shi-yin Li, Pei-fang Wang (106) Effects of water application intensity of micro-sprinkler irrigation and soil salinity on environment of coastal saline soils .................................................................................................. Lin-lin Chu, Yao-hu Kang, Shu-qin Wan (116) Responses of river bed evolution to flow-sediment process changes after Three Gorges Project in middle Yangtze River: A case study of Yaojian reach...............................................................Li-qin Zuo, Yong-jun Lu, Huai-xiang Liu, Fang-fang Ren, Yuan-yuan Sun (124) Multi-objective reservoir operation using particle swarm optimization with adaptive random inertia weights .........................................................................................Hai-tao Chen, Wen-chuan Wang, Xiao-nan Chen, Lin Qiu (136) PIV analysis and high-speed photographic observation of cavitating fl ow field behind circular multi-orifi ce plates ......................................................................................................Zhi-ping Guo, Xi-huan Sun, Zhi-yong Dong (145) Scour around submarine pipes due to high-amplitude transient waves...........................................................................................................................Hassan Vosoughi, Hooman Hajikandi (154) Deformation coordination analysis of CC-RCC combined dam structures under dynamic loads..............................................................Bo-wen Shi, Ming-chao Li, Ling-guang Song, Meng-xi Zhang, Yang Shen (162)IINo. 3Impacts of topographic factors on regional snow cover characteristics...........................................................................................................................................Muattar Saydi, Jian-li Ding (171) Evaluation of alum-based water treatment residuals used to adsorb reactive phosphorus.............................................................................................................................George Carleton, Teresa J. Cutright (181) Phosphorus removal by adsorbent based on poly-aluminum chloride sludge......................................Hui-fang Wu, Jun-ping Wang, Er-gao Duan, Wen-hua Hu, Yi-bo Dong, Guo-qing Zhang (193) Characterization of cobalt ferrite-supported activated carbon for removal of chromium and lead ions from tannery wastewater via adsorption equilibrium ..............................................................Muibat Diekola Yahya,Kehinde Shola Obayomi, Mohammed Bello Abdulkadir, Yahaya Ahmed Iyaka, Adeola Grace Olugbenga (202) Acclimatization of microalgae Arthrospira platensis for treatment of heavy metals in Yamuna River .................................................................................Nilesh Kumar, Shriya Hans, Ritu Verma, Aradhana Srivastava (214) Three-dimensional modelling of shear keys in concrete gravity dams using an advanced grillage method ...................................................................................................Mahdi Ben Ftima, Stéphane Lafrance, Pierre Léger (223) Influences of flow rate and baffle spacing on hydraulic characteristics of a novel baffl e dropshaft ..........................................................Xi-chen Wang, Jian Zhang, Zong-fu Fu, Hui Xu, Ting-yu Xu, Chen-lu Zhou (233) Influence of correlation scale errors on aquifer hydraulic conductivity inversion precision.....................................................................Yun-xiao Mu, Lei Zhu, Tong-qing Shen, Meng Zhang, Yuan-yuan Zha (243)No. 4Change of stream network connectivity and its impact on fl ood control.......................................................................................Yu-qin Gao, Yun-ping Liu, Xiao-hua Lu, Hao Luo, Yue Liu (253) Comparative evaluation of impacts of climate change and droughts on river flow vulnerability in Iran ........................................................................................................................................... ....Zahra Noorisameleh,Shahriar Khaledi, Alireza Shakiba, Parviz Zeaiean Firouzabadi, William A. Gough, M. Monirul Qader Mirza (265) Improved ecological development model for lower Yellow River fl oodplain, China................................................................................Jin-liang Zhang, Yi-zi Shang, Ji-xiang Liu, Jian Fu, Meng Cui (275) Green synthesis of bentonite-supported iron nanoparticles as a heterogeneous Fenton-like catalyst: Kinetics of decolorization of reactive blue 238 dye .......Ahmed Khudhair Hassan, Ghayda Yaseen Al-Kindi, Dalal Ghanim (286) Highly efficient tandem Z-scheme heterojunctions for visible light-based photocatalytic oxygen evolution reaction ...................................................................................Yi Lu, Xing-kai Cui, Cheng-xiao Zhao, Xiao-fei Yang (299) Batch and fixed-bed column studies of selenite removal from contaminated water by orange peel-based sorbent .............Bárbara Pérez Mora, Fernando A. Bertoni, María F. Mangiameli, Juan C. González, Sebastián E. Bellú (307) Quantifying water quality and flow in multi-branched urban estuaries for a rainfall event with mass balance method ......................................................................Joan Cecilia Casila, Gubash Azhikodan, Katsuhide Yokoyama (318) Characterizing ship-induced hydrodynamics in a heavy shipping traffic waterway via intensifi ed fi eld measurements .............................................................................................................Li-lei Mao, Yi-mei Chen, Xin Li (330) Total contents of 2020 (I)。

卡梅伦液压数据手册(第 20 版)说明书

卡梅伦液压数据手册(第 20 版)说明书
11
iv

CONTENTS OF SECTION 1
☰ Hydraulics
⌂ Cameron Hydraulic Data ☰
Introduction. . . . . . . . . . . . . ................................................................ 1-3 Liquids. . . . . . . . . . . . . . . . . . . ...................................... .......................... 1-3
4
Viscosity etc.
Steam data....................................................................................................................................................................................... 6
1 Liquid Flow.............................................................................. 1-4
Viscosity. . . . . . . . . . . . . . . . . ...................................... .......................... 1-5 Pumping. . . . . . . . . . . . . . . . . ...................................... .......................... 1-6 Volume-System Head Calculations-Suction Head. ........................... 1-6, 1-7 Suction Lift-Total Discharge Head-Velocity Head............................. 1-7, 1-8 Total Sys. Head-Pump Head-Pressure-Spec. Gravity. ...................... 1-9, 1-10 Net Positive Suction Head. .......................................................... 1-11 NPSH-Suction Head-Life; Examples:....................... ............... 1-11 to 1-16 NPSH-Hydrocarbon Corrections.................................................... 1-16 NPSH-Reciprocating Pumps. ....................................................... 1-17 Acceleration Head-Reciprocating Pumps. ........................................ 1-18 Entrance Losses-Specific Speed. .................................................. 1-19 Specific Speed-Impeller. .................................... ........................ 1-19 Specific Speed-Suction...................................... ................. 1-20, 1-21 Submergence.. . . . . . . . . ....................................... ................. 1-21, 1-22 Intake Design-Vertical Wet Pit Pumps....................................... 1-22, 1-27 Work Performed in Pumping. ............................... ........................ 1-27 Temperature Rise. . . . . . . ...................................... ........................ 1-28 Characteristic Curves. . ...................................... ........................ 1-29 Affinity Laws-Stepping Curves. ..................................................... 1-30 System Curves.. . . . . . . . ....................................... ........................ 1-31 Parallel and Series Operation. .............................. ................. 1-32, 1-33 Water Hammer. . . . . . . . . . ...................................... ........................ 1-34 Reciprocating Pumps-Performance. ............................................... 1-35 Recip. Pumps-Pulsation Analysis & System Piping...................... 1-36 to 1-45 Pump Drivers-Speed Torque Curves. ....................................... 1-45, 1-46 Engine Drivers-Impeller Profiles. ................................................... 1-47 Hydraulic Institute Charts.................................... ............... 1-48 to 1-52 Bibliography.. . . . . . . . . . . . ...................................... ........................ 1-53

ARTISAN技术集团预览说明书

ARTISAN技术集团预览说明书

Integrated 3-Axis Motion Controller/DriverController GUI ManualV2.0.xESP301 Controller GUI Manual EDH0282En1030 — 01/17iiESP301 Controller GUI Manual Table of Contents1.0Introduction (1)1.1Purpose (1)1.2Overview (1)2.0Installation (2)2.1Install ESP301 Graphical User Interface (2)2.2Launch GUI (2)3.0User Interface (3)3.1Configuration (3)3.2Axis (4)3.3Main (5)3.4Jog (7)3.5Parameters (8)3.6Diagnostics (9)3.7About (10)Service Form (11)EDH0282En1030 — 01/17iiiESP301 Controller GUI Manual EDH0282En1030 — 01/17ivESP301 Controller GUI ManualESP301Integrated 3-AxisMotion Controller/Driver1.0Introduction1.1PurposeThe purpose of this document is to provide instructions on how to use the ESP301graphical user interface (GUI).1.2OverviewThe ESP301 GUI is a graphical user interface, that allows the user to control Newportstages with the ESP301 controller (execute motion, configure stages, etc.).EDH0282En1030 — 01/171ESP301 Controller GUI Manual 2.0Installation2.1Install ESP301 Graphical User InterfaceFollowing are steps to install the ESP301 GUI:•For 32 bit, Select and launch “ESP301 Utility Installer Win32.exe”. For 64 bit,Select and launch “ESP301 Utility Installer Win64.exe”.• A window opens up showing Install welcome page.•Click on “Next”.• A window opens up allowing destination folder selection. By default it is showingC:\.•Click on “Next”.•Ready to install window opens up. Click “Install”.•Then installation starts, wait for completion. Click on “Finish” to finalize theinstallation.32 bit installer will install “mandInterface.dll” in GAC_32 folderand 64 bit installer will install the dll in GAC_64 folder.NOTELabVIEW users can add a reference of the command interface dll from GACduring VI creation.2.2Launch GUIFrom Windows “START” menu, select “All Programs\Newport\MotionControl\ESP301\ESP301 Utility”.EDH0282En1030 — 01/17 2ESP301 Controller GUI Manual 3.0User Interface3.1ConfigurationThe Configuration tab allows the user to view and / or change information related to thelogging configuration and the instrument settings. Read only values are displayed forthe log file name and the log file path.The logging level may be changed to any of the settings in the drop-down list on theright hand side. Trace is the most detailed of the settings and when this setting isselected, the GUI logs everything. Critical Error is the least detailed of the settings andwhen selected, the GUI will only log errors that are defined to be critical.The polling interval defines the number of milliseconds between each time the GUIpolls the ESP301 for the latest information. The user may change the polling intervalby entering a value.The Save button saves the current settings to the configuration file.EDH0282En1030 — 01/173ESP301 Controller GUI ManualConfigurable settingsThe following table describes all the settings that can be changed by the user.3.2AxisThe combo box at the top of the window allows the selection of axes (1 to 3).EDH0282En1030 — 01/17 4ESP301 Controller GUI Manual3.3MainThe Main tab displays the main controls in the GUI like a virtual front panel. It isupdated each time the polling interval timer expires.“Initialization and Configuration”In the “Initialization and Configuration” area, the first button switches between theLocal and Remote states. The second button turns the motor: ON or OFF and StopMotion. The Home button commands the stage to go to the home position. The lastbutton “Save Pos.” memorizes the current positions in the combo box. As soon as a newposition is memorized, this is displayed in the trace.“Current Position”In the “Current Position” area, the current position is displayed in a text box andvisualized in a slider. The slider limits are defined with the ends of run. An LED showsthe current controller state. When you move the mouse over the LED, the controllerstate is displayed in an information balloon.“Incremental Motion / PR-Move Relative”In the “Incremental Motion / PR-Move Relative” area, two steps can be defined. Foreach step, a relative move is made in the negative direction or a positive direction.EDH0282En1030 — 01/175“Cyclic Motion” and “Target position / PA-Move Absolute”In the “Cyclic Motion” area, a motion cycle is configured with a number of cycles (Cycle) and a specified time in milliseconds (dwell). The motion cycle gets the defined target positions from the “Target position / PA-Move Absolute’ area to perform the cycle.In the “Target position / PA-Move Absolute” area, two target positions can be defined. The “Go to” button executes the absolute move to go to the specified target position.“Motion Configuration Values”In the “Motion Configuration Values”, the current ends of run and the velocity are displayed in a disabled text box: “Minimum end of run”, “Maximum end of run” and “Velocity”. These ends of run and the velocity can be modified and saved with the “Set” button.Memorized positionsThe combo box memorizes the positions using the “Save Pos.” button. Each of these positions can be renamed or deleted. To execute an absolute move to go to one of these memorized positions, select one item of the combo box and click on “Go to” button. When the mouse moves over to the combo box, the positions of the selected memorized position are showed in an information balloon.Rename a memorized position: Select an item from the combo box, edit the position name to change it and click on the “Rename” button to save the new position name. Delete a memorized position: Select an item from the combo box, right-click on the mouse and select the “Delete” menu to delete the selected memorized position.3.4JogThe Jog tab allows entry of the position value in the Jog mode.“Initialization and Configuration”In the “Initialization and Configuration” area, the first button switches between theLocal and Remote states. The second button “Save Pos.” allows memorizes the currentpositions in the combo box. As soon as a new position is memorized, this is displayed inthe trace.“Current Position”In the “Current Position” area, the current position is displayed in a text box andvisualized in the slider. The slider limits are defined with the ends of run. An LEDshows the current controller state. When you move the mouse over the LED, thecontroller state is displayed in an information balloon.“Jog Motion”In the “Jog Motion” area, an indefinite move (MV) can be performed in either thenegative direction or a positive direction. Motion starts when a button is held down andstops when the button is released.“Jog Velocity”In the “Jog Velocity” area, the jog velocity can be defined. Keep in mind that theslider’s scale is logarithmic.Memorized positions (defined by axis)The combo box memorizes the positions using the “Save Pos.” button. Each of thesepositions can be renamed or deleted. To execute an absolute move to go to one of thesememorized positions, select one item of the combo box and click on “Go to” button.When the mouse moves over to the combo box, the positions of the selected memorizedposition are showed in an information balloon.Rename a memorized position: Select an item from the combo box, edit the positionname to change it and click on the “Rename” button to save the new position name.Delete a memorized position: Select an item from the combo box, right-click on themouse and select the “Delete” menu to delete the selected memorized position.3.5ParametersThe Parameters tab display and allows changes tothe parameters of the instrument.3.6DiagnosticsThe Diagnostics tab allows the user to enter instrument commands and to view thehistory of commands sent and the responses received. This list of commands and thesyntax of each command can be found in the user’s manual for the instrument.A file of commands can be sent line by line to the instrument with the “SendCommand file” button.3.7AboutThe About tab displays information about the GUI and the connected instrument. Itdisplays the GUI name, version, and copyright information. It also displays theinstrument model and instrument key (serial number).Service FormYour Local RepresentativeTel.: __________________Fax: ___________________Name: _________________________________________________ Return authorization #: ____________________________________ Company:_______________________________________________ (Please obtain prior to return of item)Address: ________________________________________________ Date: __________________________________________________ Country: ________________________________________________ Phone Number: __________________________________________ P.O. Number: ____________________________________________ Fax Number: ____________________________________________ Item(s) Being Returned: ____________________________________Model#: ________________________________________________ Serial #: ________________________________________________Description: ________________________________________________________________________________________________________ Reasons of return of goods (please list any specific problems): ________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________ __________________________________________________________________________________________________________________North America & Asia Newport Corporation 1791 Deere Ave.Irvine, CA 92606, USA SalesTel.: (800) 222-6440e-mail:*****************Technical Support Tel.: (800) 222-6440e-mail:****************Service, RMAs & Returns Tel.: (800) 222-6440e-mail:*******************EuropeMICRO-CONTROLE Spectra-Physics S.A.S 9, rue du Bois Sauvage 91055 Évry CEDEX FranceSalesTel.: +33 (0)1.60.91.68.68 e-mail:******************Technical Supporte-mail:***********************Service & ReturnsTel.: +33 (0)2.38.40.51.55Visit Newport Online at: 。

不同发病部位结肠癌临床特征及预后分析

不同发病部位结肠癌临床特征及预后分析

不同发病部位结肠癌临床特征及预后分析李昕雨;屈怡帆;李娟;白莉【摘要】目的分析不同发病部位结肠癌的临床特征和预后。

方法分析2007年1月-2010年6月在本院治疗的361例结肠癌患者资料,其中左半结肠癌194例,右半结肠癌167例。

对患者发病年龄、性别、临床表现、组织学类型、有无脉管癌栓、淋巴结转移情况、远处转移、临床分期等进行分析。

结果右半结肠癌患者与左半结肠癌相比,发病年龄较高(〉60岁,31.1%vs 18.0%),女性居多(61.1%vs 41.8%)。

右半结肠癌的首发症状主要表现为腹部疼痛(37.3%)、便血(22.8%),部分可扪及腹部包块(23.4%);左半结肠癌表现为便血(54.1%)、肠梗阻(11.3%)。

右半结肠癌与左半结肠癌低分化率(24.5%vs12.9%)及脉管癌栓率(11.4%vs 6.7%)差异有统计学意义(P〈0.05)。

右半结肠癌5年生存率69.5%,低于左半结肠癌的77.3%(P〈0.05)。

结论左、右半结肠癌临床病理特征及预后不尽相同;右半结肠癌的发病年龄更大,女性发病率更高,低分化及脉管癌栓更多见,恶性程度更高,5年生存率更低。

【期刊名称】《解放军医学院学报》【年(卷),期】2016(037)011【总页数】4页(P1142-1144,1196)【关键词】左半结肠癌;右半结肠癌;临床特征;预后【作者】李昕雨;屈怡帆;李娟;白莉【作者单位】解放军总医院肿瘤内科,北京100853【正文语种】中文【中图分类】R735.3已有研究提示直肠癌的发病率有下降趋势,而结肠癌比例逐渐升高,尤其是右半结肠癌(rightsided colon cancer,RCC)[1]。

左、右半结肠癌的胚胎起源不同,具有不同的血液供应途径、组织学类型及生物学特征,在临床治疗、对药物的敏感性、预后、生存期等方面存在不同程度的差异[2]。

本研究回顾性分析361例确诊结肠癌患者的临床病例资料并进行整合分析,比较左右半结肠癌,为不同部位结肠癌的诊疗及预后提供依据。

2014 Advanced imaging for detection and differentiation of colorectal neoplasia-ESGE Guideline

2014 Advanced imaging for detection and differentiation of colorectal neoplasia-ESGE Guideline

BibliographyDOI /10.1055/s-0034-1365348Published online:17.3.2014Endoscopy 2014;46:435–449©Georg Thieme Verlag KG Stuttgart ·New York ISSN 0013-726XCorresponding authorMicha łF.Kami ński,MD PhD Department ofGastroenterological Oncology Institute of Oncology Roentgen Street 5Warsaw PolandFax:+48225463057mfkaminski@coi.waw.plD o w n l o a d e d b y : I P -P r o x y N a t i o n a l _D e f e n s e _U n i v e r s i t y , N a t i o n a l D e f e n s e U n i v e r s i t y . C o p y r i gAbbreviations!CAC cap-assisted colonoscopy CRC colorectal cancerEMR endoscopic mucosal resectionESGE European Society of Gastrointestinal Endoscopy FAP familial adenomatous polyposisFICE Fujinon intelligent color enhancement,flexible spec -tral imaging enhancementFAP familial adenomatous polyposisGRADE grading of recommendations assessment,develop-ment and evaluationHD-WLE high definition white-light endoscopy i-SCAN Pentax virtual chromoendoscopy system MAP MUTYH -associated polyposis NBI narrow band imagingPICO population,intervention,comparator,outcome PIVI preservation and incorporation of valuable endo-scopic innovationsRCT randomized controlled trialSD-WLE standard definition white-light endoscopy TER third eye retroscope WLEwhite-light endoscopyIntroduction!Colonoscopy is widely used for colorectal cancer (CRC)detection and prevention [1,2].Its efficacy depends on the ability to detect colorectal neoplasia [3,4].In order to maximize the detection of colorectal neoplasia we may not only need to improve the exam-ination technique and quality of bowel preparation but also to engage advanced imaging technologies such as high definition endoscopy,conventional or virtual chromoendoscopy,autofluor-escence imaging (AFI)or add-on devices [5].Some of these tech-nologies may in addition help to characterize detected lesions and thereby guide decisions about endoscopic resection or en-able real-time endoscopic diagnosis.Despite being readily avail-able,most technologies have been little adopted into clinical practice outside academic settings [6],mostly because they are perceived as cumbersome,time-consuming and requiring special training.In our view,however,an important barrier to wide-spread adoption is the lack of a clear guideline on which technol-ogy is worth using in which clinical scenario.This Guideline aims to provide endoscopists with a comprehen-sive review of advanced imaging techniques available for the de-tection and differentiation of colorectal neoplasia.We also make recommendations about the circumstances under which those techniques warrant introduction into routine clinical practice.Methods!The European Society of Gastrointestinal Endoscopy (ESGE)com-missioned this Guideline.The guideline development process in-cluded meetings and online discussions among members of the guideline committee during December 2012and February 2013.Subgroups were formed,each in charge of a series of clearly de-fined key questions (●Appendix e1,available online).The guide-line committee chairs (C.H.,J.M.D.)worked with the subgroup leaders (J.P.,M.P.,R.B.,J.E.,M.F.K.)to identify pertinent search terms that included:high definition endoscopy,chromoendos-copy,virtual chromoendoscopy (always including additional sep-arate searches for NBI,FICE,and i-SCAN),autofluorescence endoscopy,and add-on devices (cap-assisted colonoscopy,Third Eye Retroscope [TER]),as well as terms pertinent to specific key questions.Techniques still under development,such as confocal laser endomicroscopy,endocytoscopy,and optical coherence to-mography,were not included in this Guideline.Technical aspects of advanced imaging technologies will be described in a separatetechnology review;they are summarized in ●Table 1.For ease of literature searching,key questions were formulated using PICO methodology [7].Searches were performed on Medline (via Pubmed)and the Co-chrane Central Register of Controlled Trials up to October 2012;additionally abstracts from the 2012United European Gastroen-terology Week and the 2012Digestive Disease Week were sear-ched.Articles were first selected by title;their relevance was then assessed by reviewing full-text articles,and publications with content that was considered irrelevant were excluded.Evi-dence tables were generated for each key question,summarizing the level of evidence of the available studies.For important out-comes,articles were individually assessed by using the Grading of Recommendations Assessment,Development and Evaluation (GRADE)system for grading evidence levels and recommenda-tion strengths [8].The GRADE system is clinically orientated as the grading of recommendations depends on the balancebe-Table 1Summary of characteristics of advanced imaging techniques.D o w n l o a d e d b y : I P -P r o x y N a t i o n a l _D e f e n s e _U n i v e r s i t y , N a t i o n a l D e f e n s e U n i v e r s i t y . C o p y r i g h t e d m a t e r i a l.tween benefits and risks or burden of any health intervention (●Appendix e2a,b ,available online).In order to answer the question on accuracy of virtual chromoendoscopy systems and AFI in differentiating between small neoplastic and non-neoplas-tic colorectal polyps,one of the subgroups performed a bivariate meta-analysis using a linear mixed model approach [9].Each subgroup developed draft proposals that were presented to the entire group for general discussion during a meeting held in February 2013(Düsseldorf,Germany).Based on evidence tables and draft proposals,key topics for further research were formu-lated.Further details on the methodology of ESGE guidelines have been reported elsewhere [10].In October 2013,a draft prepared by M.F.K.and C.H.was sent to all group members.After agreement on a final version,the manu-script was submitted to the journal Endoscopy for publication.The journal subjected the manuscript to peer review,and the manuscript was amended to take into account the reviewers ’comments.The final revised manuscript was agreed upon by all the authors.This Guideline was issued in 2014and will be considered for up-date in 2017.Any interim updates will be noted on the ESGE web-site:/esge-guidelines.html.Recommendations and statements!Evidence statements and recommendations are stated in italics,key evidence statements and recommendations are in bold.For ease of clinical use,recommendations and statements were grouped into five categories defined by target population and/or the role of advanced imaging for detection and/or differentiation of colorectal neoplasia.Statements on the use of virtual chromo-endoscopy mention in parentheses the type of technology (NBI,FICE or i-SCAN),which was proven to be effective.The summaryof the recommendations is presented in ●Fig.1.Detection of colorectal neoplasia in average riskpopulations!The term “average risk population ”is most widely used in the setting of CRC screening [11,12].For the purpose of this Guide-line,this term applies to all patients outside the setting of colitis or hereditary syndromes.As a large number of colonoscopies are performed in average risk populations [13],even minor increases in neoplasia detection rates achieved in this population maytranslate into a large effect on absolute numbers of CRC preven-ted.On the other hand,an advanced imaging technology should be very practical and cost-effective in order not to overload al-ready stressed health care systems if it is to be recommended for average risk populations.ESGE suggests the routine use of high definition white-light endos-copy systems for detecting colorectal neoplasia in average risk popu-lations (weak recommendation,moderate quality evidence).A meta-analysis of five studies that included 4422average risk patients showed a 3.5%(95%confidence interval [95%CI]0.9%–6.1%)incremental yield from high definition white-light endos-copy (HD-WLE)over standard definition white-light endoscopy (SD-WLE)for the detection of patients with at least one adenoma [14].There were no differences between HD-WLE and SD-WLE for high risk adenomas.We postulate that the difference in the fields of view of the endoscopes that were used is unlikely to ac-count for the increased yield observed with HD-WLE because three randomized controlled trials (RCTs),from two centers,found no significant difference in polyp detection rates between SD-WLE with 140°and 170°fields of view [15–17].In a two-cen-ter RCT published after the meta-analysis [18],the proportion of participants in whom adenomas were detected was higher with HD-WLE compared with SD-WLE (45.7%vs.38.6%;P =0.166)and the difference was significant in the proportions of patients with flat adenomas (9.5%vs.2.4%;P =0.003)and with right-sided ade-nomas (34.0%vs.19.0%;P =0.001).The cost –effectiveness of adopting HD-WLE in routine practice was not studied.High defi-nition colonoscopes are available from all major manufacturers.ESGE does not suggest routine use of conventional pancolonic chro-moendoscopy in average risk populations,despite its proven bene-fit,for practical reasons (weak recommendation,high quality evi-dence).A recent Cochrane systematic review [19]analyzed five RCTs (to-tal 1059patients)that assessed the role of conventional chromo-endoscopy in detecting colorectal lesions outside the setting of polyposis or colitis.Pancolonic chromoendoscopy significantly increased the number of patients with at least one polyp detect-ed (odds ratio [OR]2.22,95%CI 1.55–3.16)and of those with at least one dysplastic lesion detected (OR 1.67,95%CI 1.29–2.15).A limitation of the systematic review was the significant hetero-geneity observed between the studies.Since the publication of this Cochrane systematic review,four RCTs have compared HD-WLE with conventional chromoendos-copy for detecting neoplastic lesions [20–23].Only one of themAdvanced Colonoscopic ImagingDetection Average-risk populationLynch/serrated polyposis syndromeUlcerative colitis Diminutive polypsHigh-definition white-light endoscopy Conventional or virtual chromoendoscopy Conventional chromoendoscopyConventional or virtual chromoendoscopyMargins: all large NPL Invasion: NPL 0-IIc/NG-LSTPiecemeal polypectomy scarCharacterizationFig.1Summary of the recommendations.NPL,nonpolypoid lesion;0-IIc,lesions with a depressed component;NG-LST,non-granular laterally spreadingD o w n l o a d e d b y : I P -P r o x y N a t i o n a l _D e f e n s e _U n i v e r s i t y , N a t i o n a l D e f e n s e U n i v e r s i t y . C o p y r i g h t e d m a t e r i a l.[22]did not find that conventional chromoendoscopy detects sig-nificantly more adenomas than HD-WLE (32.7%vs.26.9%;P =0.47).However this study only evaluated the detection of adeno-mas located in the distal colon and in the rectum.The other three studies [20,21,23]showed that chromoendoscopy increased the overall detection of adenomas,including flat and small adeno-mas.None of the studies showed an increased detection rate for advanced neoplastic lesions but none of them was sufficiently powered for this aim.In expert hands,additional procedure duration associated with pancolonic chromoendoscopy was 4–10minutes in all studies that reported this item,i.e.,a 30%–40%increase in total proce-dure duration [20,23].Additional costs associated with dyes,re-moval,and histopathological evaluation of additional non-neo-plastic lesions and the increase in total procedure duration,cou-pled with the absence of evidence supporting an increased detec-tion rate of advanced neoplasia,call against the routine use of pancolonic chromoendoscopy in average risk populations.ESGE does not recommend routine use of virtual pancolonic chro-moendoscopy,AFI,or add-on devices for detecting colorectal neo-plasia in average risk populations (strong recommendation,high quality evidence).Virtual chromoendoscopyTwo recent meta-analyses of RCTs compared detection [24,25]and miss rates [25]of colonic lesions in average risk populations using white-light endoscopy (WLE)and NBI.In the meta-analysis [24],of 7RCTs,that included a total of 2936patients,there was no significant difference in adenoma detection rate between NBI and WLE (36%vs.34%,P =0.413;relative risk [RR]1.06,95%CI 0.97–1.16).The other meta-analysis [25],included 9RCTs [26–34](3studies published in abstracts only),and a total of 3059pa-tients.This meta-analysis also showed no difference between HD-NBI and HD-WLE for the detection of adenomas (OR 1.01,95%CI 0.74–1.37),of patients with adenomas (OR 1.0,95%CI 0.83–1.20),of flat adenomas (OR 1.26,95%CI 0.62–2.57),nor in the miss rate of adenomas (OR 0.65,95%CI 0.40–1.06).Two re-cent large,multicenter RCTs [18,35]further corroborated the re-sults of these meta-analyses.Data on the use of FICE or i-SCAN for detection of colonic neopla-sia during colonoscopy are scarce.Two RCTs [36,37]did not find any difference between HD-FICE and HD-WLE concerning adeno-ma detection [36]or adenoma miss rate [37]in screening or sur-veillance colonoscopies.The single RCT that compared HD-i-SCAN with HD-WLE for screening colonoscopy showed no signif-icant difference either in adenoma detection or in the adenoma miss rates [38].NBI and FICE are often criticized for darkening the endoscopy im-age and in turn hampering the wider view of the colon [24].Whether newer-generation,brighter systems make a difference in adenoma detection remains to be evaluated.Autofluorescence endoscopyFive RCTs evaluating AFI for the detection of colorectal neoplasia in average risk patients have produced conflicting results [39–43].Details of these studies are summarized in ●Appendix e3(available online).A tandem study of AFI vs.HD-WLE [41]showed significantly lower proximal adenoma miss rates with AFI.Another RCT,from Japan [42],that allocated patients to four groups:HD-WLE alone,HD-WLE +cap-assisted colonoscopy [CAC],AFI alone,AFI +CAC,found a significantly higher number of adenomas per patient in the AFI +CAC group compared withthe HD-WLE alone group.In contrast,all three tandem RCTs that were conducted in Europe have not demonstrated differences in colorectal adenoma miss rates between AFI and HD-WLE in aca-demic settings [40,43]or between AFI and SD-WLE in a nonaca-demic setting [39].Add-on devicesFour meta-analyses,published in 2011and 2012,have compared the efficacy of CAC with that of regular colonoscopy [44–47].Three of them [44–46]included between 7and 14RCTs for the analysis of detection of colorectal lesions;one considered avail-able data regarding polyp detection not adequate for meta-anal-ysis [47].All three meta-analyses demonstrated a significantly higher polyp detection rate (by 8%–13%)but no difference in the adenoma detection rate between CAC and regular colonosco-py.Therefore,the role of CAC for the detection of colorectal neo-plasia is limited.One multicenter,tandem colonoscopy RCT compared the detec-tion of adenomas using the “third eye ”retroscope (TER)with reg-ular colonoscopy in an average risk population [48].The per-pro-tocol analysis showed that more adenomas were missed with regular colonoscopy compared with the TER (RR 1.92;95%CI 1.07–3.44)but the difference was not statistically significant in the intention-to-treat analysis (RR 1.46,P =0.185).The total pro-cedure and withdrawal times were 4and 2minutes longer with TER,respectively,because of device manipulation and additional polypectomies.The utility of TER in routine practice is further limited by technical difficulties with the use of the device in 5%of patients [48],impaired ability to aspirate luminal contents,re-latively high cost [49],and limited availability.Detection of colorectal neoplasia in hereditary syndromes!Advanced imaging,compared with regular colonoscopy,can po-tentially help in hereditary syndromes in two principal ways.First,it can assist in making a diagnosis by revealing additional lesions required to meet diagnostic criteria for sessile serrated and adenomatous polyposis syndromes [50,51].Second,when a hereditary CRC syndrome is diagnosed and surveillance is under-taken,advanced imaging may lead to better lesion detection thereby reducing the risk of interval cancer [52]or allowing the safe extension of surveillance intervals.ESGE recommends the routine use of high definition pancolonic chro-moendoscopy in patients with known or suspected Lynch syndrome (conventional chromoendoscopy,NBI,i-SCAN)or serrated polyposis syndrome (conventional chromoendoscopy,NBI)(strong recommen-dation,low quality evidence).Patients and family members with Lynch syndrome or serrated polyposis syndrome are recommended frequent,usually annual to biennial colonoscopy surveillance [53,54]in order to minimize the risk of developing interval cancer [55,56].In both syndromes,precursor lesions are more likely to be nonpolypoid,located proximally,and difficult to recognize [54,57,58].Four small tan-dem colonoscopy studies [59–62],showed higher detection rates of adenomas [59–61]or polyps [62]with conventional chromo-endoscopy compared with SD-WLE or HD-WLE in patients with Lynch syndrome,at the cost of additional time (range 1.8to 17D o w n l o a d e d b y : I P -P r o x y N a t i o n a l _D e f e n s e _U n i v e r s i t y , N a t i o n a l D e f e n s e U n i v e r s i t y . C o p y r i g h t e d m a t e r i a l.minutes per case)(the studies are summarized in ●Appendix e4,available online).The role of virtual chromoendoscopy in patients with Lynch syn-drome was assessed in two prospective cohort studies [61,63]and one RCT [64].In the first cohort study [63]an additional pass with NBI significantly increased the proportion of patients detected with adenomas (absolute difference 15%,95%CI 4%–25%)compared to a single pass with HD-WLE.In the other cohort study [61]the total numbers of adenomas and flat adenomas de-tected by a second pass with conventional chromoendoscopy were significantly higher than with a first pass using HD-NBI.In a tandem RCT [64]the miss rate of polyps was significantly lower with i-SCAN compared with HD-WLE (16%vs.52%,respectively;P <0.01).A tandem RCT compared specifically AFI (Xillix Technologies Cor-poration)with HD-WLE in patients with Lynch syndrome or fa-milial CRC [65].The sensitivity for the detection of adenomas was significantly higher with AFI compared with HD-WLE (92%vs.68%,P =0.01).The AFI system used in this study is not widely commercially available.Although there are no studies that have assessed conventional chromoendoscopy in sessile serrated poly-posis,a review that summarized serrated lesion detection in an average risk population suggested that conventional chromoen-doscopy doubled the detection rate of serrated lesions,overall and in the proximal colon (no differentiation between hyperplas-tic and sessile serrated polyps was made)[51].One tandem colo-noscopy RCT in patients with sessile serrated polyposis [66]showed significantly lower polyp miss rates with HD-NBI com-pared with HD-WLE (OR 0.21;95%CI 0.09–0.45).One pilot study showed suboptimal diagnostic accuracy of AFI in differentiation between sessile serrated polyps,hyperplastic polyps,and adeno-mas [67].ESGE does not make any recommendation for the use of advanced endoscopic imaging in patients with suspected or known familial adenomatous polyposis (FAP)including attenuated and MUTYH-associated polyposis (insufficient evidence to make a recommenda-tion).Patients with classical FAP have hundreds of adenomas uniformly distributed in the colorectum while those with attenuated FAP and MUTYH -associated polyposis (MAP)have much fewer,more proximally distributed,adenomas.For surveillance,sigmoidosco-py is recommended in patients with classical FAP and colonosco-py in those with attenuated FAP or with MAP [68,69].In patients with classical FAP,conventional and virtual chromoendoscopy in-crease the detection rate of adenomas compared with HD-WLE [70];however the clinical usefulness of these techniques is lim-ited,because of the recommendation for proctocolectomy early in the course of the disease.In the context of attenuated FAP and of MAP,the usefulness of these techniques during surveillance is unknown.Following proctocolectomy for FAP,small adenomas are better detected in the ileal pouch with conventional chromoendoscopy [71,72]but the clinical significance of this finding is unclear.Detection and differentiation of colorectal neoplasia in long-standing inflammatory bowel disease!Patients with long-standing left-sided or extensive ulcerative co-litis or extensive Crohn ’s colitis are recommended to have inten-sive colonoscopic surveillance because of an increased risk of CRC compared with the average risk population [53,73].Advancedimaging may be of benefit by:(i)increasing the detection of dys-plasia [74];(ii)improving the differentiation of lesions (colitis associated neoplasia,sporadic neoplasia [75,76],and non-neo-plastic lesions);and (iii)reducing the number of unnecessary biopsies.ESGE recommends the routine use of 0.1%methylene blue or 0.1%–0.5%indigo carmine pancolonic chromoendoscopy with targeted biopsies for neoplasia surveillance in patients with long-standing co-litis.In appropriately trained hands,in the situation of quiescent dis-ease activity and adequate bowel preparation,nontargeted four-quadrant biopsies can be abandoned (strong recommendation,high-quality evidence).Two sufficiently powered RCTs compared the diagnostic yield of conventional chromoendoscopy and SD-WLE [77,78].Addition-ally,one high quality meta-analysis [79]including these two RCTs and four cohort studies confirmed the overall findings in 1277patients from a well-defined target population (disease duration >8years).In the meta-analysis the pooled incremental yield of conventional chromoendoscopy with random biopsies over SD-WLE with random biopsies for the detection of patients with neoplasia was 7%(95%CI 3.2%–11.3%).Moreover,the dif-ference in proportion of lesions detected by targeted biopsies only was 44%(95%CI 28.6%–59.1%)in favor of conventional chromoendoscopy.Two prospective cohort studies [80,81]pub-lished after the meta-analysis further corroborated the results.Overall,in 8prospective studies comparing conventional chro-moendoscopy with SD-WLE,the former consistently increased the proportion of patients found with dysplasia with a factor 2.08–3.26[77–81].Although in all the abovementioned studies [77–81]random four-quadrant biopsies were taken as a back-up method in con-junction with chromoendoscopy-targeted biopsies,the diagnos-tic yield of those back-up biopsies was rather limited.The pooled sensitivity for the detection of neoplasia with chromoendoscopy-targeted biopsies only was 86%(range 71%–100%)for all studies that reported this data and 95%(range 87%–100%)after exclu-sion of one study [82]in which targeted rather than pancolonicchromoendoscopy was used (●Appendix e5,available online;[77,78,80–82,83,84,85]).The median number of targeted biop-sies sampled per procedure was 1.3(range 0.28–14.2)and the median number of targeted plus random biopsies per procedure was 34.3(range 7.0–42.2).The number of biopsies needed during conventional chromoen-doscopy surveillance of long-standing colitis can therefore be sig-nificantly reduced if only targeted biopsies are taken.The case for abandoning random biopsies is further supported by evidence of poor adherence to endoscopic protocols for random biopsies in clinical practice [86].There is however no evidence to show what the process of pancolonic chromoendoscopy training and abandoning random biopsies should look like.It has been sug-gested during expert discussion at the Disease Digestive Week 2009(T.A.Ullman and R.Kiesslich)that the following logical steps should be undertaken:(i)chromoendoscopy training with an expert on at least 30colonoscopies;(ii)chromoendoscopy with targeted and random biopsies;(iii)chromoendoscopy with random biopsies in special situations only (multiple post-inflam-matory polyps,neoplasia on previous colonoscopy,etc);and (iv)chromoendoscopy with targeted biopsies only.In studies summarized in the meta-analysis cited above [79],the duration of surveillance colonoscopy in long-standing colitis wasD o w n l o a d e d b y : I P -P r o x y N a t i o n a l _D e f e n s e _U n i v e r s i t y , N a t i o n a l D e f e n s e U n i v e r s i t y . C o p y r i g h t e d m a t e r i a l.longer with pancolonic chromoendoscopy plus random biopsies compared with SD-WLE with random biopsies,by an average 11minutes (95%CI 10min 15s to 11min 43s).It is likely,however,that the duration of pancolonic chromoendoscopy with only tar-geted biopsies is comparable to or shorter than that of WLE with random biopsies [84,85].In all prospective studies [77–81]0.1%methylene blue or 0.1–0.5%indigo carmine solutions were used for chromoendoscopy,with no evidence for difference in their efficacy.Some concern was raised by a report on oxidative DNA damage in Barrett ’s epi-thelium caused by methylene blue in combination with photo-sensitization by WLE [87],but there is no clinical evidence indi-cating an increased risk in patients with long-standing colitis.Limitations of conventional chromoendoscopy in the context of long-standing colitis surveillance needs to be mentioned.There is no proof that better detection of neoplasia by conventional chromoendoscopy translates into reduced CRC mortality or de-creased risk of interval CRC.Cost –effectiveness is also unclear for chromoendoscopy compared to WLE plus random biopsies,although it may be cheaper when combined with risk stratifica-tion thereby entailing fewer colonoscopies and fewer histological samples [88].It is unknown whether there would be any benefits of conventional chromoendoscopy over WLE with newer-genera-tion HD-WLE colonoscopes.Several prerequisites are listed in the SURFACE guidelines [89],such as quiescent disease and excellent bowel preparation,which must be met in the performance of pancolonic chromoendoscopy surveillance.Nevertheless the use of pancolonic chromoendoscopy with only targeted biopsies for dysplasia detection in colitis is now strongly endorsed by the British Society of Gastroenterology [90],and the European Crohn ’s and Colitis Organization [91].ESGE found insufficient evidence to recommend for or against the use of virtual chromoendoscopy or autofluorescence imaging (AFI)for the detection of colorectal neoplasia in inflammatory bowel dis-ease (insufficient evidence to make a recommendation).Three RCTs compared virtual chromoendoscopy (NBI in all cases)with WLE for the detection of neoplasia in long-standing inflam-matory bowel disease [92–94].Regardless of generation of NBI and the level of definition of colonoscopes used,virtual chromo-endoscopy did not significantly increase the detection rate of neoplastic lesions compared with WLE [92–94].However,in all three RCTs,virtual chromoendoscopy with targeted biopsies alone yielded neoplasia detection rates comparable to WLE with targeted and nontargeted four-quadrant biopsies [92–94].Mean number of biopsies per patient was 0.5to 3.5in NBI with targeted biopsies only and 24.6to 38.3in WLE with targeted and random quadrantic biopsies [92,94].Two RCTs compared an HD-NBI system with high definition con-ventional chromoendoscopy,both without nontargeted biopsies,for the detection of neoplasia in long-standing inflammatory bowel disease [95,96].The first study was a single-center,cross-over RCT aimed at comparing neoplasia miss rates with HD-NBI and high definition conventional chromoendoscopy [95].The miss rate of neoplastic lesions was considerably higher with HD-NBI compared with high-definition conventional chromoendos-copy (31.8%and 13.6%,respectively)but the study was not pow-ered enough to test the observed difference for statistical signifi-cance.The second study was a multicenter,parallel group RCT aimed at comparing neoplasia detection rates with HD-NBI and high definition conventional chromoendoscopy [96].Preliminary results (108of 134planned patients have been included)showed similar neoplasia detection rates for NBI and conventional chro-moendoscopy,per lesion (24.0%and 17.2%,respectively;P =0.385)and per patient (18.5%and 16.7%,respectively).Median withdrawal time was significantly shorter in the NBI group com-pared to the chromoendoscopy group (21vs.27minutes,respec-tively;P =0.003).There were only two studies,of which one was an RCT,compar-ing HD-WLE with AFI for the detection of colorectal neoplasia in inflammatory bowel disease [94,97].A pilot study [97]showed that protruding lesions with a low autofluorescence signal were significantly more likely to be neoplastic than lesions with a high autofluorescence signal (45.0%vs.13.3%,respectively,P =0.043).In the RCT,the miss rate for neoplastic lesions was statistically significantly lower with AFI compared with HD-WLE (0%vs.50%,P =0.036).It should be noted that inadequate bowel preparation and active inflammation interrupt tissue autofluorescence,result-ing in discoloration on AFI and resembling neoplasia [97].Further studies including comparison with conventional chromoendos-copy are needed.ESGE recommends taking biopsies from flat mucosa surrounding neoplastic lesions and taking biopsies from or resecting all suspi-cious lesions identified at neoplasia surveillance in long-standing colitis,because there is no evidence that nonmagnified convention-al or virtual chromoendoscopy can reliably differentiate between colitis-associated and sporadic neoplasia or between neoplastic and non-neoplastic lesions (strong recommendation,low to mod-erate quality evidence).Neoplastic vs.non-neoplastic lesionsA modified pit pattern classification has been used in three con-ventional chromoendoscopy studies to differentiate between neoplastic and non-neoplastic lesions in long-standing inflam-matory bowel disease [77,80,82].The surface staining pattern al-lowed differentiation between neoplastic and non-neoplastic le-sions with high sensitivity and specificity (93%–100%and 88%–97%,respectively)[77,80,82].However,in the reported studies magnifying endoscopes,which are not widely available,were used for lesion characterization and total procedure times were on average 9–11minutes longer.No studies report on differen-tiation between neoplastic and non-neoplastic lesions in inflam-matory bowel disease using nonmagnifying colonoscopes with conventional chromoendoscopy.Four studies evaluated the role of non-magnified NBI in differen-tiating neoplastic and non-neoplastic lesions in patients with long-standing colitis [94,98–100].One case report [100]and one pilot study [99]showed that a tortuous pit pattern and a high vascular pattern intensity may help to distinguish neoplastic and non-neoplastic lesions in long-standing colitis.In two small RCTs [94,98]the sensitivity and specificity of NBI in predicting histology were unsatisfactory.In one of these RCTs [94]combin-ing AFI with NBI increased sensitivity for predicting histology from 75%to 100%without a major drop in specificity.No other virtual chromoendoscopy systems were assessed for differentia-tion of lesions in the setting of colitis.Colitis-associated vs.sporadic neoplasiaCurrent guidelines suggest taking biopsies from the flat mucosa surrounding neoplastic lesions in long-standing colitis,because differentiation between colitis-associated and sporadic neoplasia is crucial in determining their optimal management [73,90].Al-though it has been suggested that conventional chromoendosco-py cannot distinguish these two entities because of a similar staining pattern [89],it has recently been shown that magnifyingD o w n l o a d e d b y : I P -P r o x y N a t i o n a l _D e f e n s e _U n i v e r s i t y , N a t i o n a l D e f e n s e U n i v e r s i t y . C o p y r i g h t e d m a t e r i a l.。

特比奥与巨和粒治疗恶性实体瘤化疗后血小板减少的临床疗效比较

特比奥与巨和粒治疗恶性实体瘤化疗后血小板减少的临床疗效比较

特比奥与巨和粒治疗恶性实体瘤化疗后血小板减少的临床疗效比较魏阳;周行;周进;谢华;王理阳;赵新;姚文秀【摘要】目的观察比较特比奥(重组人血小板生成素,rhTPO)与巨和粒(重组人白细胞介素11,rhIL-11)治疗恶性实体瘤患者化疗后血小板减少的临床疗效和毒副反应.方法将化疗后出现血小板减少症的76例恶性实体瘤患者随机分成两组,其中一组38例患者在化疗后采用特比奥皮下注射治疗.另外一组38例患者在化疗后采用巨和粒皮下注射治疗,动态监测注射特比奥或巨和粒后患者血小板增长情况,c2检测比较二者临床疗效和不良反应.结果患者注射特比澳与巨和粒后血小板计数均显著升高,血小板计数恢复至100×109/L以上所需时间明显缩短,其中特比澳组血小板计数普遍高于巨和粒组,两组比较差异具有统计学意义(P<0.05),总缓解率特比澳组高于巨和粒组,差异具有统计学意义(P<0.05).8例患者在巨和粒治疗后需要输注血小板,而特比澳组只4例需要输注血小板,差异有统计学意义.二组均出现一定程度的毒副反应,其中特比奥组(13.2%)低于巨和粒组(18.4%),差异无统计学意义,两组毒副反应均比较轻微,患者可以耐受.结论特比澳与巨和粒治疗恶性实体瘤患者化疗后血小板减少症安全有效,可以减轻化疗引起的血小板降低程度和持续时间,减少血小板的输注.【期刊名称】《当代医学》【年(卷),期】2017(023)030【总页数】4页(P60-63)【关键词】重组人血小板生长因子;白细胞介素11;血小板减少症;恶性实体瘤【作者】魏阳;周行;周进;谢华;王理阳;赵新;姚文秀【作者单位】四川省肿瘤医院肿瘤内科,四川成都610041;四川省肿瘤医院肿瘤内科,四川成都610041;四川省肿瘤医院肿瘤内科,四川成都610041;四川省肿瘤医院肿瘤内科,四川成都610041;四川省肿瘤医院肿瘤内科,四川成都610041;四川省肿瘤医院肿瘤内科,四川成都610041;四川省肿瘤医院肿瘤内科,四川成都610041【正文语种】中文骨髓抑制是恶性实体瘤放化疗后的常见并发症,严重的血小板减少不仅导致出血,还影响肿瘤患者化疗方案实施甚至迫使患者中断化疗。

亚磷酸三乙酯 光催化 eda复合物

亚磷酸三乙酯 光催化 eda复合物

亚磷酸三乙酯光催化 eda复合物下载提示:该文档是本店铺精心编制而成的,希望大家下载后,能够帮助大家解决实际问题。

文档下载后可定制修改,请根据实际需要进行调整和使用,谢谢!本店铺为大家提供各种类型的实用资料,如教育随笔、日记赏析、句子摘抄、古诗大全、经典美文、话题作文、工作总结、词语解析、文案摘录、其他资料等等,想了解不同资料格式和写法,敬请关注!Download tips: This document is carefully compiled by this editor. I hope that after you download it, it can help you solve practical problems. The document can be customized and modified after downloading, please adjust and use it according to actual needs, thank you! In addition, this shop provides you with various types of practical materials, such as educational essays, diary appreciation, sentence excerpts, ancient poems, classic articles, topic composition, work summary, word parsing, copy excerpts, other materials and so on, want to know different data formats and writing methods, please pay attention!基于给定的题目"亚磷酸三乙酯光催化eda复合物",我撰写了以下中文示例文章。

近年来国内外缺血性卒中的研究热点

近年来国内外缺血性卒中的研究热点

·述评·631中国临床医生杂志 2021 年第49卷第6期近年来国内外缺血性卒中的研究热点马浩源,赵岩,吕佩源*(河北省人民医院,河北石家庄 050051)关键词:缺血性脑卒中;静脉溶栓;机械取栓;颅内动脉非急性闭塞再通中图分类号:R741 文献标识码:A 文章编号:2095-8552(2021)06-0631-03doi:10.3969/j.issn.2095-8552.2021.06.001缺血性脑卒中是国内外专家、学者共同关注的重点疾病之一。

目前,有关该病静脉溶栓、机械取栓及颅内动脉非急性闭塞再通治疗出现了较多热点研究成果,现述评如下。

1 静脉溶栓静脉溶栓是急性缺血性脑卒中(acute ischemic stroke,AIS)恢复脑血流的重要措施之一。

近年来,众多学者对静脉溶栓治疗有了一些新的认识。

1.1 从时间窗到组织窗的转变 随着影像评估的不断深入,静脉溶栓从时间窗理念逐渐扩展到了组织窗理念。

2019年发表的基于MRI或CT灌注指导的EXTEND研究[1]及CAMPBELL等[2]进行的一项荟萃分析,均认为通过多模影像评估组织窗,溶栓的时间窗可从4.5h扩展到9h。

同时,2019年《美国心脏协会/美国卒中协会指南》[3]新增了对醒后卒中或发病不明距最后正常/基线状态>4.5h的AIS患者的溶栓推荐,若扩散加权成像(DWI)病灶<大脑中动脉供血区的1/3且液体衰减反转恢复(FLAIR)成像上未见异常信号改变,在发现症状后4.5h内给予静脉阿替普酶溶栓是合理的。

此外,2020年THOMALLA等[4]纳入了WAKE-UP、EXTEND、THAWS和ECASS-4试验的荟萃分析显示,对于卒中发作时间不明的DWI-FLAIR或灌注不匹配的患者,静脉使用阿替普酶90天改良Rankin评分(mRS)优于安慰剂或标准治疗。

对于醒后卒中、发病时间不明卒中患者,可行多模影像学评估,进一步筛选符合溶栓的患者。

吉西他滨联合奥沙利铂治疗晚期胆囊癌临床对照研究

吉西他滨联合奥沙利铂治疗晚期胆囊癌临床对照研究

吉西他滨联合奥沙利铂治疗晚期胆囊癌临床对照研究【摘要】目的:观察吉西他滨联合奥沙利铂组成的GEM0X方案治疗晚期胆囊癌的有效性和安全性。

方法:晚期胆囊癌33例随机分成两组,观察组17例采用GEMOX方案,对照组16例采用FAP联合化疗,分别观察和评价其疗效和毒性。

结果:观察组部分缓解5例,无变化7例,进展5例,有效率为%;对照组PR 4例,SD 6例,PD 5例,有效率为%,两组差异无统计学意义。

观察组与对照组Ⅲ/Ⅳ级中性粒细胞下降分别为3例、6例,Ⅲ/Ⅳ级血小板下降分别为2例、1例,Ⅲ/Ⅳ级恶心呕吐分别为2例、7例。

结论:吉西他滨联合奥沙利铂组成的GEMOX 方案静脉化疗对于晚期胆囊癌的疗效与FAP 组相当,但毒副反应较轻,患者易于耐受。

【关键词】晚期胆囊癌;吉西他滨;奥沙利铂;化学治疗原发性胆囊癌的发病率在消化道肿瘤中占第5位,恶性程度高,症状不典型,发现时多为晚期[1],手术切除率低,对放化疗敏感性差,预后较差。

我科自2004年6月~2008年5月期间,将33例晚期胆囊癌患者随机分成两组,分别予吉西他滨联合奥沙利铂方案和FAP方案进行化疗。

1 资料和方法一般资料 33例中男14例,女19例;年龄38~73岁,中位年龄岁。

按全部病例均经病理及影像学检查确诊为原发性胆囊癌Ⅳ期,预计生存时间3个月。

其中初诊即为原发性胆囊癌伴肝或腹腔转移13例,术后复发肝或腹腔多发转移20例,有可供评价的肿瘤病灶,Karnofsky评分≥60分,无化疗禁忌证。

33例患者随机分成两组,观察组17例,男8例,女9例;年龄38~70岁,中位年龄55岁;对照组16例,男6例,女10例;年龄40~73岁,中位年龄57岁,两组性别、年龄、病程等指标相似,经统计学处理具有可比性。

治疗方法观察组17例给予吉西他滨1000 mg/m2及奥沙利铂85 mg/m2静脉滴注,d1、d8。

对照组16例给予阿霉素 30 mg/m2静推,d1;氟尿嘧啶500 mg/m2持续静滴,d1~d5;DDP 25 mg/m2静滴,d1~d3。

桑德斯3D打印机Model X材料最佳实践指南说明书

桑德斯3D打印机Model X材料最佳实践指南说明书

Version 1.1,February 2022Model X Material Best PracticeManufacturer:EnvisionTEC US LLCA Desktop Metal Company15162 S. Commerce Dr.Dearborn,Table of ContentsAbout Model X (3)Identification (3)Applicable Printers (3)Getting Started (4)Primary Supplies (4)Capture Patient Data (4)Design Models for Model X (5)Software (6)Orient Models Envision One RP Software (6)Support Models Envision One RP Software (6)Print Preparation (7)Mix Material (7)Fill Material Tray (7)Print with Model X Material (7)Post-Processing (8)Clean Printed Models (8)Dry Models (9)Post Cure Printed Models (9)About Model XIdentificationModel X with its 50-micron build layer allows for exceptionally detailed crowns, bridges with removable dies, implant cases and diagnostic and orthodontic models.This technical guide details the best practices for preparing models, post-processing, and finishing. Applicable PrintersThis material is tested and approved for the following printers:•Einstein™•Envision One cDLM•D4K ProGetting StartedPrimary SuppliesThe following supplies are required to print Model X material:•99% isopropyl alcohol (IPA).•Air compressor.•Cone-shaped paint filter, Starter Kit item.•Curing unit: Otoflash, SAP Part # ACC-00-0007, or PCA 4000 SAP Part # ACC-06-1000•Disposable aluminum loaf pan.•Dual Motion Bottle Roller, SAP Part # ACC-26-1000 (110V) and ACC-26-1000 (220V).•Nitrile gloves.•Paint scraper, Starter Kit item.•Paper towels.•Plastic funnel.•Rubber spatula, Starter Kit item.•Spray bottle with 99% IPA.•Snips, precision blade, or similar tool.•Storage container for material, sealable and opaque.•Washing unit: PWA 2000, SAP # ACC-22-2000.Capture Patient DataA digital impression can be accomplished with a handheld intraoral scanner and CBCT scan, or with a traditional impression and a desktop box scanner.Envision One RP Software is compatible with the universal .STL file format and is thus compatible with almost all dental CAD and model design software as well as digital design services. Models may be designed in-house or outsourced to a design partner.Design Models for Model XHollow dental models printed in Model X must have a minimum wall thickness of 3 mm, Fig. 2.It is recommended to add channels or drainage holes to hollow models. This allows uncured material to drain from the hollow feature during the printing process.SoftwareOrient Models Envision One RP SoftwareOrient models in Envision One RP Software with the flat base side down, parallel with the build platform.•Spacing: place models a minimum of 1.5 mm apart.•Level at build platform: place unsupported models 0 mm from the build platform. Place supported models 4 mm from the build platform.•Resolution: 50 µm Z resolution.Support Models Envision One RP SoftwareSome approved applications require supports. Always use the Model X.ini support file for supports –•Minimum support base: 1.0 mm•Minimum contact tip: 0.45 mm•Minimum support beam height: 4.0 mmPrint PreparationMix MaterialModel X material must be mixed in the material bottle prior to use:1.Place the sealed material bottle on the Dual Motion Bottle Roller for a minimum of 60 minutes.2.Wait for bubbles to subside before filling the material tray.3.Mix material in the material tray gently with the rubber spatula from the Starter Kit before eachprint. The material should be a uniform color.Ensure there are no small cured particles in the material. If found, then the material must be filtered using the plastic funnel, cone-shaped paint filter, and a spare material bottle. See the Knowledge Base for filtering instructions.Fill Material TrayDo not overfill the material tray. Overfilling can cause the material to overflow when the build platform moves down at the start of the print job.To add more material to the printer, carefully pour material into the material tray between prints. Adding material while the print is paused, or during a print, will cause a small shift line in the model.See the Knowledge Base for instructions adding material.Print with Model X MaterialTo start the print, follow instructions in the printer’s User Manual.To remove the models from the build platform after the print is complete, follow instructions in the printer’s User Manual. See the Knowledge Base for the latest User Manual.Post-ProcessingClean Printed ModelsThe PWA 2000 is the recommended parts washer, Fig. 4. Always wear gloves when handling uncured material and alcohol.Important:Do not expose Model X to alcohol for longer than 5 minutes. Excessexposure to alcohol may cause discoloration and warping.Clean models the PWA 2000:1.Open the washing compartment lid.2.Lift the handle to raise the interior grate to the highest position.4.Place the model on the grate and gently lower the handle to submerge the model in 99% IPA.5.Close the washing compartment lid and lock in place.6.Plug in the power cable to turn on the PWA-2000.ing the touchscreen, select the High washing program. Set the timer to 00:03:00, or 3 minutes.Press Start.→The PWA 2000 will immediately begin the set washing cycle.8.Remove the model as soon as the program is complete.9.Spray the models with the spray bottle filled with 99% IPA.e compressed air to remove all IPA from the surface of the model as soon as possible.Dry ModelsModels must be completely dry before post curing –1.Place the models on a clean paper towel lined surface.2.Air dry in ambient room temperature / humidity for 10 min.Post Cure Printed ModelsCure the models using the following method:Otoflash:2 cycles for 500 flashes, flip models between cycles.See the Knowledge Base for instructions setting an Otoflash curing cycle.PCA 4000:1 Minute - 20° C - 100% Power.See the Knowledge Base for instructions setting a PCA 4000 curing cycle.Place models into the curing unit with as much space between models as possible. Models should never touch one another while curing. Let models cool completely before handling them or starting the next cycle. Flip models between cycles for an even cure.Important: Desktop Health does not support third-party curing units.。

AMD Radeon ProRender plug-in for Universal Scene D

AMD Radeon ProRender plug-in for Universal Scene D

AMD Radeon ProRenderplug-in for Universal Scene DescriptionInstallation Guide This document is a guide on how to install and configure AMD Radeon™ ProRender p lug-in for Universal Scene Description (USD).DISCLAIMERThe information contained herein is for informational purposes only and is subject to change without notice. While every precaution has been taken in the preparation of this document, it may contain technical inaccuracies, omissions, and typographical errors, and AMD is under no obligation to update or otherwise correct this information. Advanced Micro Devices, Inc. makes no representations or warranties with respect to the accuracy or completeness of the contents of this document, and assumes no liability of any kind, including the implied warranties of non- infringement, merchantability or fitness for particular purposes, with respect to the operation or use of AMD hardware, software or other products described herein. No license, including implied or arising by estoppel, to any intellectual property rights is granted by this document. Terms and limitations applicable to the purchase or use of AMD’s products are as set forth in a signed agreement between the parties or in AMD's Standard Terms and Conditions of Sale.©2018 Advanced Micro Devices, Inc. All rights reserved. AMD, the AMD arrow, AMD FirePro, AMD Radeon Pro, AMD Radeon ProRender and combinations thereof are trademarks of Advanced Micro Devices, Inc. in the United States and/or other jurisdictions. Windows is a registered trademark of Microsoft Corporation in the United States and/or other jurisdictions. Other names are for informational purposes only and may be trademarks of their respective owners.Table of Contents Supported Platforms (2)Operating System (2)Requirements (2)Join the Discussion (2)USD Setup (3)Prerequisites (Production Version) (7)AMD Radeon ProRender Setup (8)OVERVIEW 1OVERVIEW This plug-in allows fast GPU or CPU accelerated viewport rendering on all OpenCL™hardware for the open source USD and Hydra system. This document will guide the user on how to install and configure AMD Radeon™ ProRender plug-in for Universal Scene Description (USD).Note: The implementation of this solution is not intended to be performedby end users of USD supported applications. In addition, an intermediatelevel developer knowledge base is expected from the users following thisguide. End users should proceed with support from their IT department.For more details on USD, please visit the web site here.SUPPORTED PLATFORMS 2 Supported PlatformsOperating System•Microsoft Windows® 10 (64-bit)•Ubuntu® 16.04.3•CentOS 7.5•MacOS® High Sierra 10.13.3+Requirements•Python 2.7Join the DiscussionProvide feedback here for all AMD Radeon ProRender plug-ins.USD SetupThe following steps should be followed by the setup a demo build of Pixar USD including AMD ProRender™ for testing on Windows®:1.Download and u nzip the “usd.zip” file at any location i.e. C:\USD2.Install Python 2.7.Note: Python 2.7 can be downloaded from 3.Open Command Prompt and run “C:\Python27\Scripts\pip install PySide” and“C:\Python27\Scripts\pip install OpenGL”4.The user will need to set the needed environment variables. All the environmental variables will usethe C:\USD location in them. To set the environment variables:a.Open Start Menu and type “Environment variables”.b.Click on “Edit the system Environment variables”.c.Click on “Environment variables” button on the bottom right of the window.d.Click on “New” for user variables to add these user variables below:: PXR_PLUGINPATH_NAME, Value: C:\USD\lib\python\rpr: PYTHONPATH, Value: C:\USD\lib\pythone.Click on variable “Path” to select it, click edit and add these values below:i.C:\USD\libii.C:\USD\biniii.C:\USD\plugin\usd5.Open Command Prompt and run “usdview some_usd_da”.Where “some_usd_da” canbe any USD file. Using file “Kitchen_da” as an example below:6.Once the USD file opens, In the View men, select “VIEW -> Hydra Renderer -> RPR”ers can also click on the “RPR” menu to select render modes and the device to use.ers can also use USDView controls/shortcuts to change camera views of the render screen e.g:a.ALT + Right-Click = Zoom Camerab.ALT + Left-Click = Rotate Camerac.ALT + Middle-Click = Scan CameraNote: Aforementioned instructions are needed to use the USD plug-in as a demo for testing on windows®. However, Instructions from GitHub on the following page are listed to build the plug-in as a production version.PREREQUISITES 7 Prerequisites (Production Version)There are three main requirements for the AMD Radeon ProRender plug-in for USD to build a production version which are as follows:1.An existing USD build/treeIt is possible for the USD users to get the USD libraries from different locations or compile their own.Users can download USD from GitHub to build themselves.2.AMD Radeon™ ProRender SDKContact AMD for access to ProRender SDK libraries.3.BuildingThe User can build the library using “cmake”. There are some necessary variables that the user needs to set before proceeding further. The variables are as follows:-USD_ROOT– This variable should be set to the USD installed directory.-RPR_LOCATION–This variable should be set to the AMD Radeon™ ProRender directory with include and library directories.-CMAKE_INSTALL_PREFIX– This is the location where the plug-in will be installed. It is recommended that this location matches USD_ROOT location.Note: Variables below may be automatically detected.-BOOST_ROOT - These are necessary libraries to link the plugin. If the user installed USD, these libraries will already exist. However, if the Python build script was used to install USD, this is likely to be the same as USD_ROOT.-TBBROOTBelow is an example of a cmake build:PRORENDER SETUP 8 AMD Radeon ProRender Setup1.Set up the environment variables specified by the script as it finishes and launch “usdview” with asample asset. For example:2.Select Radeon™ ProRender as the render plug-in.Note:To add the AMD Radeon™ ProRender menu added to USDView, which would allowselecting devices and view modes, set up the environment variable as:PXR_PLUGINPATH_NAME=${USD_ROOT}/lib/python/rprWhere USD_ROOT is the USD install directory set up by the useAMD Radeon ProRender plug-in for USD Installation Guide ©2018 Advanced Micro Devices, Inc. All rights reserved.AMD Radeon ProRenderplug-in for Universal Scene DescriptionInstallation GuideWritten by: Hassan Tauseef08/13/2018©2018 Advanced Micro Devices, Inc.All rights reserved.。

Schneider Electric Conext Automatic Generator Star

Schneider Electric Conext Automatic Generator Star

Conext Automatic Generator StartThe Conext TM Automatic Generator Start (AGS) can automatically activate or stop a generator in response to changing power requirements. An excellent addition to an off-grid or backup power system, the AGS seamlessly connects to the Xanbus TM network and shares status information with all other devices on the network. It can monitor a set of system user-programmable parameters such as battery voltage, state of charge or grid power and can activate the generator in response to any changes. The AGS can also be configured remotely using the Conext System Control Panel (SCP) or Conext ComBox to engage a generator, and can assist an inverter/charger when output power demands are high.Automatically start and stop a generator to meet power needsTrue bankability • W arranty from a trusted partner with over 177 years of experience• W orld leader in industrial power drives, UPS and electrical distribution• S trong service infrastructure worldwide to support your global needsHigher return on investment• I ntegrate with an inverter/charger to maximize system power performance Designed for reliability • T ested and qualified for harsh environmental conditions (HALT reliability testing)Flexible • W orks with multiple Xanbus devices - Conext XW, SW, MPPT 60-150, MPPT 80-600, SCP , ComBox• U ser-programmable trigger settings to meet specific application needs° B attery voltage°SOC °E xercise time °Q uiet time° I nverter / charger AC power loads• Supports manual start and stop operation modesEasy to service • A ccess and troubleshoot AGS device events using the Conext ComBox or SCP• E asily upgrade new firmware to the AGS using the ComBoxEasy to install • W all mount• R J45 connections for Xanbus network cables© 2014 Schneider Electric. All rights reserved. Schneider Electric, Conext, and Xanbus are trademarks owned by Schneider Electric Industries SAS or its affiliated companies. All other trademarks are the property of their respective owners.DS20140826_AGSDevice short name Conext Automatic Generator StartElectrical specificationsNominal input network voltage 15 VdcMax. operating current 200 mA @ nominal input network voltageRelay contact voltage rating 12 Vdc, 30 Vdc max*Max. relay contact current 5 A DC*Nominal 12/24 V thermostat input voltage 12 Vdc / 24 Vdc* = OnMin. 12/24 V thermostat input voltage 9.5 Vdc*Max. 12/24 V thermostat input voltage 30 Vdc*Typical 12/24 V thermostat input current 14.6 mA @ 12 VNominal 12/24 V generator running B+ voltage 12 Vdc / 24 Vdc* = OnMin. 12/24 V generator running B+ voltage 9.5 Vdc*Max. 12/24 V generator running B+ voltage 30 Vdc*Typical 12/24 V generator running B+ voltage 14.6 mA @ 12 VGeneral specificationsDimensions (H x W x D) 9.55 x 14.6 x 3.7 cm (3.8 x 5.7 x 1.5 in)Weight 225.0 g (0.5 lb)Mounting options Wall-mountIP rating / location IP20, indoor onlyWarranty 2 to 5 years (depending on country)Part number 865-1060-01CommunicationNetwork protocol XanbusConnectors 2 x RJ45 portsRegulatory approvalsSafety CSA 107.1-01, UL 458 4th Ed including the Marine Supplement EMC F CC Part 15B Class B, Industry Canada ICES-0003 Class B Included parts One network terminatorOne CAT5 cable (2.1 m)One mounting plateFour #6 screwsSpecifications are subject to change without notice. *Limited to Class 2 levels (100 VA)Conext MPPT 80 600solar charge controllerProduct no. 865-1032System Control PanelProduct no. 865-1050-01Conext ComboxCommunication deviceProduct no. 865-1058Conext Battery MonitorProduct no. 865-1081-01。

铝掺杂对氧化锌基摩擦纳米发电机输出性能的影响

铝掺杂对氧化锌基摩擦纳米发电机输出性能的影响

铝掺杂对氧化锌基摩擦纳米发电机输出性能的影响林金堂; 李典伦; 阮璐; 丘志榕; 王嘉鑫【期刊名称】《《电子元件与材料》》【年(卷),期】2019(038)010【总页数】5页(P39-43)【关键词】摩擦纳米发电机; 掺铝氧化锌薄膜; 溶胶-凝胶法; 正摩擦材料; 垂直接触-分离模式【作者】林金堂; 李典伦; 阮璐; 丘志榕; 王嘉鑫【作者单位】福州大学物理与信息工程学院福建福州 350108【正文语种】中文【中图分类】TB34摩擦纳米发电机(TENG)具有质量轻、体积小、成本低廉、制备工艺简单、稳定性好、使用寿命长等一系列优点,在能源领域和移动电子设备领域有着广泛的应用前景[1-5]。

目前,相关工作主要集中在研究优化TENG结构及负摩擦材料[6-10],而优化正摩擦材料对改善TENG输出性能也同样重要[11]。

氧化锌(ZnO)是一种宽带隙半导体材料,具有优异的物理和化学性能,其制备简单,绿色环保,作为正摩擦材料在TENG及自驱动传感器领域具有良好的应用前景[12-13],因此研究优化ZnO失电子能力以提升TENG输出性能具有重要意义。

为了提高以ZnO为正摩擦材料的TENG输出性能,可采用物理改性增加ZnO表面粗糙度以增大正负摩擦材料的有效接触面积,从而提高摩擦过程中电荷转移量[14-15];另一方面,通过改变掺杂种类和掺杂浓度可增强ZnO失电子能力[16],从而提升TENG输出性能。

在掺杂 ZnO系列材料中,铝掺杂氧化锌(AZO)具有失电子能力较强、电学性能可优化、化学稳定性高和机电耦合性良好等优点[17],因此对ZnO进行Al掺杂是提高ZnO基TENG输出性能的有效方法。

本文采用溶胶-凝胶工艺制备AZO 薄膜,以其作为正摩擦材料制备垂直接触-分离结构的TENG,研究Al掺杂浓度对AZO基TENG输出性能的影响。

1 实验1.1 AZO薄膜的制备采用溶胶-凝胶法制备AZO薄膜,获得Al掺杂浓度为摩尔分数2%~20%的AZO 薄膜,本实验所用的化学试剂均购买自上海阿拉丁生化科技股份有限公司,其具体制备过程如下:(1)AZO溶胶的制备:将二水合醋酸锌在室温条件下溶解在50 mL的乙二醇甲醚中,并使用磁力搅拌器搅拌1 h,配置成锌离子浓度为0.6 mol/L的溶液。

相关主题
  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

Copyright WILEY‐VCH Verlag GmbH & Co. KGaA, 69469 Weinheim, Germany, 2015.Supporting Informationfor Adv. Mater., DOI: 10.1002/adma.201503461Structure-Tuned Lead Halide Perovskite Nanocrystals Yasser Hassan, Yin Song, Ryan D. Pensack, Ahmed I. Abdelrahman, Yoichi Kobayashi, Mitchell A. Winnik, and Gregory D. Scholes*Supporting InformationStructure-Tuned Lead Halide Perovskite NanocrystalsYasser Hassan, Yin Song, Ryan D. Pensack, Ahmed I. Abdelrahman, Yoichi Kobayashi, Mitchell A. Winnik and Gregory D. ScholesContentsI. Additional experimental details (2)FluorimeteryFluorescence quantum yield (2)II. Photographs of lead iodide and corresponding perovskite nanocrystals (3)Transmission Electron Microscopy of PbI2 NCs (4)Transmission Electron Microscopy (4)Experimental Selected Area Electron Diffraction (SAED) (5)Simulated SAED (5)Ligand and solvent effects on the optical properties of perovskite NCs (7)Details of powder X-ray diffraction (PXRD) measurements including samplepreparation (8)X–ray photoelectron spectroscopy (XPS) (10)Time-Correlated Single Photon Counting Measurements for 2D Perovskite NCs (n=3) (12)References (13)Additional experimental details1A.Fluorimetry. Fluorescence spectra were obtained and fluorescence quantum yield (FQY)measurements were performed on a PTI Quantum Master Fluorimeter (PhotonTechnology International, Inc., Birmingham, NJ) consisting of a Xenon lamp, a double excitation monochromator, a single emission monochromator, and a Hamamatsu R928 photomultiplier tube. Slit widths were set to 1.2 mm for both excitation and emission monochromators for measurements of the perovskite nanocrystal fluorescence spectra.Typical scan parameters were 2 nm steps and 1.0 s integration time.B.Fluorescence quantum yield. The relative fluorescence quantum yield measurement wascarried out on solution with a maximum O.D. of <0.05 in a 1 cm path length quartz cell (Starna Cells, Inc., Atascadero, CA). Cresyl violet in methanol (FQY=0.54)[1] was used asa fluorescence quantum yield standard. Cresyl violet was chosen, in particular, as itsfluorescence spectrum exhibits significant overlap with that of the perovskite nanocrystal photoluminescence (i.e., specifically n=3 perovskite). Spectranalyzed methanol (Fischer) was used as the solvent for cresyl violet. A mixture of spectrophotometric-gradechloroform and toluene was used as the solvent for the perovskite nanocrystals. Theexcitation wavelength was set at 530 nm. The slit widths were chosen to maximize the signal for the dye, while staying within the linear range of the detector response. The dye and perovskite nanocrystal samples were excited at the same wavelength to ensure that each were exposed to the same intensity of light. The solutions were not deoxygenated prior to measurements. Cresyl violet in air- and nitrogen-saturated solutions exhibitidentical fluorescence intensities [1]; loss of the volatile methyl ammonium iodidecomponent within the perovskite nanocrystal suspension caused the perovskitenanocrystals to degrade under nitrogen-saturation.2I.Photographs of lead iodide and corresponding perovskite nanocrystalsComparing the solution color before and after the treatment of the PbI2 NCs shows a change from a pale yellow to a red solution, the latter being representative of the color of the 2D lead iodide perovskite NCs (Fig. S1).Figure S1. Photograph of a colloidal lead iodide NC suspension and the corresponding 2D organo-lead iodide perovskite NCs. a, Photograph of a colloidal lead iodide NC suspension in toluene and the corresponding 2D organo-lead iodide perovskite (n= 3) NCs in mixture of toluene: chloroform (2:1) under exposure to ambient and UV light. (b) Photograph of a colloidal 2D perovskite (n=3) suspension in a mixture of chloroform and toluene.3II.Transmission Electron Microscopy of PbI2 NCsA.Transmission Electron MicroscopyFigure S2.Transmission Electron Microscopy of PbI2 NCs.a,TEM images of PbI2 NCs prepared at 160 o C. b,c, High-resolution electron microscopy (HRTEM) of the PbI2 NCs. d, Fast Fourier transform (FFT) of the HRTEM image showing the (101), (102), (111) and (004) lattice fringes.4B.Experimental Selected Area Electron Diffraction (SAED)Selective Area Electron Diffraction (SAED) patterns for a collection of PbI2 nanocrystals deposited on a carbon grid (Figure S3) were obtained using transmission electron microscopy (TEM; JEOL 2010 at 200 kV).Figure S3. Experimental selected area electron diffraction (SAED) patterns of PbI2 NCs.SAED image of PbI2 NCs of size 10 nm prepared at 200 o C, 30 minutes growth.C.Simulated SAEDElectron diffraction patterns were simulated with open-source software GDIS[2] andDiffraction Ring Profiler[3] using the space group information of the hexagonal phase of PbI2 (PDF card no 43-1484). The latter software package integrates the SAED ring patternintensities to accurately calculate the center point of each ring. The simulated SAED pattern can be found in Figure Fig S4.5Figure S4. Experimental and simulated selected area electron diffraction (SAED) patterns of PbI2 NCs. a, Comparison of the SAED of PbI2 NCs and the simulated XRD patterns of the PbI2 hexagonal structure (PDF card no. 43-1484). b, Integrated SAED and simulated XRD patterns of PbI2 NCs. The simulation of the SAED was performed using open-source software Diffraction Ring Profiler.6III.Ligand and solvent effects on the optical properties of perovskite NCsFigure S5. Absorption spectra of perovskite NCs synthesized with different ligands and solvent mixture ratios. a, Absorption spectra of perovskite NCs synthesized with butyl-, octyl-, and olelyl-ammonium ligands. b, Absorption spectra of perovskite NCs synthesized with olelylammonium ligand with different solvent mixture ratios, i.e., toluene (T) to chloroform (CF) = 2:1, 1:1 and 1:1.5 v/v ratio.7IV.Details of powder X-ray diffraction (XRD) measurements including sample preparationX-ray patterns for phase purity were recorded on a Rigaku MiniFlex Benchtop X-ray diffractometer (equipped with Cu Kα X-ray tube) operating at 600 watts (tube voltage 40 kV and 15 mA) with a time per step of 3 s at range of = 0–60 degree. Samples were rotated during data collection.In order to study the effect of PbI2 sample preparation method on the PXRD, we prepared films by two different methods: (i) methanol treatment method and (ii) spin coating without methanol treatment.(i) Methanol treatment methodPbI2 NCs were purified by iteratively precipitating in methanol and subsequently re-dissolving in toluene in order to remove excess and weakly bound surface ligands (Figure S6a).(ii) Spin coatingIn this method the PbI2 NC solution in hexane, toluene or chloroform were spin coated on a silicon substrate. The thickness of the deposited films was 10-20 nm. The film was dried by flushing with nitrogen gas prior to the XRD measurements (Figure S6b).Perovskite NCs did not undergo the removal of excessive ligands; i.e. the diffractogram of the perovskite NCs was obtained on a powder of nanocrystals that had been prepared by evaporating the toluene:chloroform solution after deposition on a silicon substrate at room temperature from a concentrated NCs colloidal solution. The diffractogram of the 2D perovskite NCs (in case of n=1 and 2) was obtained on a powder of nanocrystals while the diffractogram of the 2D perovskite NCs (n=3) was performed on film prepared by spin coating.Calculating the d-spacing from XRD peaks:8From Braggs’ law, we calculated the interplanar distance, i.e. the d-spacing.2θhkl=2arcSin (λ2d hkl ) , then d hkl =(h2a2+k2b2+l2c2)−12where a, b, and c are the cell parameters, d hkl is the interplanar distance.For plane (002); the d002=c/2 or c=2*d002Figure S6 shows the powder X-ray diffraction (XRD) pattern of the 3D organo-lead halide perovskite NCs (CH3NH3PbI3) prepared by mixing the PbI2 NCs with excess MAI and spin coated on a glass substrate. This substrate was treated by heating at 70-100 o C for 5 minutes before undergoes measurements. This heating lead to the crystal phase transformation to the three dimensional lattice.Figure S6a (blue line) shows strong reflection peaks at 14.03o, 28.13o, 28.3o and 31.67o, corresponding to the (002), (004), (200) and (222) planes, respectively, indicate high crystallinity of a typical diffraction pattern of a tetragonal perovskite phase (space group I4/mcm)[4]. The FWHM of the XRD peaks indicate that the NCs aggregated upon evaporation to form a larger particle size (several tens nanometer). The strong diffraction peaks at 2θ =19.55 and 29.57 o (starred) can be attributed to unreacted excess MAI precursor[5]. The absence of the PbI2 peak in the perovskite XRD spectrum suggests complete conversion of PbI2 NCs to perovskite which is in agreement with absorption spectrum of perovskite in Figure 2b.9Figure S6. Powder X -ray diffraction (XRD) measurements of PbI 2 and the corresponding 2D organo -lead iodide perovskite NCs. a , X–ray diffractogram of PbI 2 after washing by methanol (red) and after the transformation to lead halide perovskite (blue). The blue line indicates the XRD results for perovskite powder , which was deposited on a silicon substrate at room temperature from a concentrated colloidal NCs solution without any further treatment, while PbI 2 NCs were precipitated using a methanol/heptane mixture before centrifugation and collection for measurements. Perovskite reflection peaks are assigned to the tetragonalperovskite crystal lattice except the peaks at 19 and 29 degrees coming from the unreacted precursors. * denote diffraction peaks corresponding to unreacted precursors and not from the perovskite. The plot displays the X–ray intensity as a function of twice the diffraction angle (2 ). b , X–ray diffractogram of PbI 2 films deposited by spin coating without washing (black line) and the calculated XRD spectra of PbI 2 hexagonal phase (red line).baV.X–ray photoelectron spectroscopy (XPS)The spin-orbit splitting between the Pb 4f7/2 and Pb 4f5/2 core levels and between I 3d5/2 and I 3d3/2 core levels are 4.86 and 11.5 eV, respectively; which are similar to values previously reported[6, 7] for lead halide perovskites. In order to determine the stoichiometry and chemical environments present in the NCs, the peaks were fitted according to a Gaussian-Lorentzian peak shape along with a ‘Smart’ background. Quantifying the values of the area under the peaks, we calculated the ratio of Pb:I and found it to be 3:10 corresponding to 2D (n= 3)OL2(CH3NH3)2[Pb3I10] perovskite (where OL = oleylamine) and molar ratio 2:7 in case of 2D (n=2) OL2CH3NH3[Pb2I7] and these results are consistent in all samples measured. In the case of iodide peaks of the perovskite NCs (n=3), it was found when we used the Gaussian fitting the presence of a small peak at 617 eV (4 % of the total iodide in the sample) which corresponds to the iodide bond in the excess of unreacted methyl ammonium iodide[7].Figure S7.Representative X–ray photoelectron spectroscopy (XPS) analysis of a, Pb 4f core level and b, I 3d core level of 2 D perovskite film deposited from evaporated NCs solution. XPS showing the Pb(II) 4f7/2 and 4f5/2 transitions with a binding energy of 137.8 eV and 142.7 eV respectively with no metallic Pb component observed, and I 3d5/2 and 3d3/2 transitions with a binding energy of 619.28 and 630.78 eV, respectively. c and d, Gaussian-Lorentzian peak shape fitting along with a ‘Smart’ background of Pb 4f core level and I 3d core level of 2 D perovskite NCs.Figure S8. X–ray photoelectron spectroscopy (XPS) analysis of PbI2 NCs. a, Gaussian-Lorentzian peak shape fitting along with a ‘Smart’ background of a, Pb 4f core level and b, I 3d core level of PbI2 NCs film deposited from evaporated NCs solution. XPS showing the Pb(II) 4f7/2 and 4f5/2 transitions with a binding energy of 138.5 eV and 143.42 eV respectively with no metallic Pb component observed, and I 3d5/2 and 3d3/2 transitions with a binding energy of 619.18 and 630.68 eV, respectively.VI.Time-Correlated Single Photon Counting Measurements for 2D Perovskite (n=3)TCSPC measurements of the 2D perovskite (n=3)nanocrystal suspension. The excitation wavelength was 374 nm and the emission wavelength was 646 nm. Overlaying the data (black) is a biexponential fit (red) with time constants of 14 and 46 ns.Table S1. Amplitudes and Time Constants Obtained from Biexponential Fit to TCSPC Measurements on 2D Perovskite (n=3) Nanocrystal SuspensionVII.References[1] D. Magde, J. H. Brannon, T. L. Cremers, J. Olmsted, The Journal of Physical Chemistry 1979, 83, 696.[2]S. Fleming, A. Rohl, Zeitschrift fur Kristallographie 2005, 220, 580.[3]L. Zhang, C. M. B. Holt, E. J. Luber, B. C. Olsen, H. Wang, M. Danaie, X. Cui, X. Tan, V. W. Lui, W. P. Kalisvaart, D. Mitlin, The Journal of Physical Chemistry C 2011, 115, 24381.[4]J. Burschka, N. Pellet, S.-J. Moon, R. Humphry-Baker, P. Gao, M. K. Nazeeruddin, M.Grätzel, Nature 2013, 499, 316; T. Baikie, Y. Fang, J. M. Kadro, M. Schreyer, F. Wei, S. G. Mhaisalkar, M. Graetzel, T. J. White, Journal of Materials Chemistry A 2013, 1, 5628; D. Shi, V. Adinolfi, R. Comin, M. Yuan, E. Alarousu, A. Buin, Y. Chen, S. Hoogland, A. Rothenberger, K. Katsiev, Y. Losovyj, X. Zhang, P. A. Dowben, O. F. Mohammed, E. H. Sargent, O. M. Bakr, Science 2015, 347, 519; J.-H. Im, C.-R. Lee, J.-W. Lee, S.-W. Park, N.-G. Park, Nanoscale, 3, 4088; A. Kojima, K. Teshima, Y. Shirai, T. Miyasaka, Journal of the American Chemical Society 2009, 131, 6050.[5]N. J. Jeon, J. H. Noh, Y. C. Kim, W. S. Yang, S. Ryu, S. I. Seok, Nat Mater 2014, 13, 897.[6]R. Lindblad, D. Bi, B.-w. Park, J. Oscarsson, M. Gorgoi, H. Siegbahn, M. Odelius, E. M. J. Johansson, H. Rensmo, The Journal of Physical Chemistry Letters 2014, 5, 648.[7]T.-W. Ng, C.-Y. Chan, M.-F. Lo, Z. Q. Guan, C.-S. Lee, Journal of Materials Chemistry A 2015, 3, 9081.。

相关文档
最新文档